

1 **Estimated global and regional incidence and prevalence of herpes**  
2 **simplex virus infections and genital ulcer disease in 2020:**  
3 **Mathematical modeling analyses**

4 Manale Harfouche, MPH<sup>1,2</sup>, Sawsan AlMukddad, MSc<sup>1,2</sup>, Asalah Alareeki, MPH<sup>1,2</sup>, Aisha M. M.  
5 Osman, MSc<sup>1,2</sup>, Sami L. Gottlieb, MD<sup>3</sup>, Jane Rowley, PhD<sup>4</sup>, Laith J. Abu-Raddad, PhD<sup>1,2,5,6,7\*</sup>,  
6 and Katharine J. Looker, PhD<sup>8\*</sup>

7 <sup>1</sup> *Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University,*  
8 *Qatar Foundation - Education City, Doha, Qatar*

9 <sup>2</sup> *World Health Organization Collaborating Centre for Disease Epidemiology Analytics on*  
10 *HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar,*  
11 *Cornell University, Qatar Foundation - Education City, Doha, Qatar*

12 <sup>3</sup> *Department of Sexual and Reproductive Health and Research, World Health Organization,*  
13 *Geneva, Switzerland.*

14 <sup>4</sup> *Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health*  
15 *Organization, Geneva, Switzerland.*

16 <sup>5</sup> *Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New*  
17 *York, New York, USA*

18 <sup>6</sup> *Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha,*  
19 *Qatar*

20 <sup>7</sup> *College of Health and Life Sciences, Hamad bin Khalifa University, Doha, Qatar*

21 <sup>8</sup> *Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United*  
22 *Kingdom*

23 *\*These authors are joint senior authors of this work.*

24 **Word count:** Abstract: 299 words, Text: 3,992 words.

25 **Number of tables:** 5

26 **Running head:** 2020 HSV-1 and HSV-2 global and regional estimates.

27 **Keywords:** Epidemiology; mathematical modelling; herpes simplex virus; genital herpes; genital  
28 ulcer disease, global; sexually transmitted infection.

29 **Funding:** The World Health Organization (Global HIV, Hepatitis and STIs Programmes)  
30 supported this work through a grant from USAID.

31 **Reprints or correspondence:**

32 Professor Laith J. Abu-Raddad, Infectious Disease Epidemiology Group, World Health  
33 Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually  
34 Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine - Qatar, Qatar Foundation -  
35 Education City, P.O. Box 24144, Doha, Qatar. Telephone: +(974) 4492-8321. Fax: +(974) 4492-  
36 8333. E-mail: [lja2002@qatar-med.cornell.edu](mailto:lja2002@qatar-med.cornell.edu).

37 Dr Katharine Looker, Population Health Sciences, Bristol Medical School, University of Bristol,  
38 Oakfield House, Oakfield Grove, Bristol BS8 2BN, United Kingdom. E-mail:  
39 [katharine.looker@bristol.ac.uk](mailto:katharine.looker@bristol.ac.uk).

40

41 **Abstract**

42 **Background:** Genital herpes simplex virus (HSV) type 1 and 2 infections are lifelong and can  
43 cause symptomatic genital ulcer disease (GUD). HSV-2 almost always causes sexually  
44 transmitted genital infection, while HSV-1 mainly causes oral infection but can be sexually  
45 transmitted to cause genital infection. This study estimated genital infection with both HSV types  
46 and associated GUD globally in 2020, breaking down the data by World Health Organization  
47 (WHO) region and sex for females and males.

48 **Methods:** A calibrated mathematical model was employed to generate estimates for the  
49 incidence and prevalence of HSV-2 infection, genital HSV-1 infection, and GUD caused by both  
50 HSV types. Estimates for non-genital infections caused by HSV-1 were also generated. Model  
51 input was derived from a comprehensive systematic review and meta-analyses of HSV  
52 prevalence data for all WHO regions.

53 **Results:** Globally in 2020 there were 25.6 million (95% uncertainty interval (UI): 23.1-29.4  
54 million) people aged 15 to 49 years with new HSV-2 infections and 519.5 million (95% UI:  
55 464.3-611.3 million), or 13.3% (95% UI: 11.9-15.6%), with existing (prevalent) HSV-2  
56 infections. In addition, there were 16.8 million (95% UI: 10.6-22.4 million) people aged 15-49  
57 years with new genital HSV-1 infections and 376.2 million (95% UI: 235.6-483.5 million), or  
58 10.2% (95% UI: 6.4-13.1%), with prevalent genital HSV-1 infections. The estimated number of  
59 people aged 15 to 49 years with at least one episode of HSV-attributable genital ulcer disease in  
60 2020 was 187.9 million (95% UI: 116.0-291.8 million) for HSV-2 and 16.7 million (95% UI:  
61 9.3-25.2 million) for HSV-1, totaling 204.6 million (95% UI: 132.3-306.5).

62 **Conclusion:** Genital HSV infections have a high incidence and prevalence worldwide,  
63 contributing to a significant GUD disease burden. New prevention and treatment measures, such

- 64 as prophylactic and therapeutic HSV vaccines, are critically needed to control HSV infections
- 65 and reduce the associated disease burden.

## 66 **Introduction**

67 Herpes simplex virus (HSV) type 1 and type 2 cause lifelong infections and are widespread  
68 worldwide, resulting in significant disease and economic burden [1-3]. Both infections are  
69 characterized by frequent infectious subclinical shedding, along with symptomatic reactivations  
70 in a proportion of those infected [4-8]. HSV-2 infection is almost always acquired through sexual  
71 transmission and is the leading cause of recurrent clinical genital ulcer disease (GUD) in most  
72 countries [9-12]. In addition to the painful genital sores, genital herpes is associated with a range  
73 of social and psychological adverse outcomes, including effects on sexual relations, quality of  
74 life, and mental health issues such as depression, anxiety, and low self-esteem [13-16]. HSV-2  
75 infection is believed to increase the risk of HIV acquisition and transmission by threefold [17,  
76 18], potentially resulting in an epidemiological synergy between these two infections [18-20].  
77 HSV-1 infection is typically acquired orally in childhood and commonly manifests as cold sores  
78 [21, 22], but it can also cause more serious neurological, corneal, and mucocutaneous  
79 complications [23-25]. Adults can acquire genital HSV-1 infection if they were not infected  
80 orally during childhood [26]. Particularly in high-income countries, HSV-1 infection has been  
81 increasingly acquired sexually [9, 26-28], and in several countries, it is now the leading cause of  
82 first-episode genital herpes [9, 27, 28]. Recurrences of genital HSV-1 are much less frequent  
83 compared to HSV-2 recurrences [4].  
84 HSV-1 and HSV-2 infections can both be transmitted, albeit rarely, from genitally-infected  
85 mothers to their neonates during birth and through oral contact from caregivers postnatally [29],  
86 leading to neonatal herpes, a disabling disease in newborns with a high fatality rate [14, 30]. In  
87 response to the clinical disease burden of these two infections and their impact on sexual and  
88 reproductive health and HIV transmission, the World Health Organization (WHO) has advocated

89 for efforts to reduce HSV disease burden by advancing the development of new prevention and  
90 treatment measures, such as vaccines [31].

91 In this article, we present global and regional modeling estimates of the incidence and prevalence  
92 of genital HSV infections as well as HSV-related genital ulcer disease (GUD) for the year 2020.

93 In addition to updating earlier estimates [1, 32, 33], the present estimates benefit from  
94 methodological enhancements. The main enhancement is that HSV-1 and HSV-2 prevalence  
95 data, which provided the modeling input, are based on a series of standardized and  
96 comprehensive HSV systematic reviews, meta-analyses, and meta-regressions covering all  
97 global regions, published over the last few years [9-12, 27, 28, 34-40].

## 98 **Methods**

### 99 **Model input**

100 The model input was provided by the databases of the published systematic reviews [9-12, 27,  
101 28, 34-40]. Since the reviews were published over several years [9-12, 27, 28, 34-40], and  
102 considering the lag of a few years between sample collection and data publication [9-12, 27, 28,  
103 34-40], an update was done up to March 30, 2022, to ensure completeness and inclusion of the  
104 most recent data for each WHO region. However, only data based on samples collected up to  
105 2020 were used for the modeling input. Since the regional groupings of countries in the  
106 published reviews were not WHO region groupings, country-level data were re-grouped into the  
107 six WHO regions. While the details of the standardized methodology of the reviews have been  
108 published previously [9-12, 27, 28, 34-40], a summary is provided in Box S1 of the  
109 Supplementary Material for inclusiveness.

110 The validity of each HSV diagnostic assay for each data point was investigated, considering  
111 known limitations of HSV serology and potential cross-reactivity between HSV-1 and HSV-2  
112 antibodies [41, 42]. This assessment was conducted in consultation with Professor Rhoda  
113 Ashley-Morrow of the University of Washington, an expert in HSV diagnostic methods. Only  
114 studies with valid and reliable assays were included in the systematic reviews.

115 Data were synthesized based on methods used to generate the 2016 WHO HSV estimates [1], but  
116 with adjustments to improve on study methodology, to incorporate recent findings on HSV-1 and  
117 HSV-2 epidemiology, and to account for limitations in available data for specific regions (Box  
118 S1). These adjustments are summarized in Box S2. Inclusion criteria for HSV-1 was an antibody  
119 prevalence (seroprevalence) measure in a general population aged 0-49 years with a midpoint of  
120 2004 up to 2020 for the year of data collection (and 1995 up to 2020 for the African and South-  
121 East Asia regions due to poor data availability). Inclusion criteria for HSV-2 was an antibody  
122 prevalence measure among a general population aged 15-49 years with a midpoint of 2004 up to  
123 2020 for the year of data collection.

124 Meta-analyses were conducted using the DerSimonian-Laird random-effects models [43] with  
125 the Freeman-Tukey double arcsine transformation [44]. Pooled mean HSV-1 and HSV-2  
126 prevalences were calculated by sex (when possible) and by age. In this simplified representation  
127 of populations, we stratified populations into two groups, “females” and “males”; however, we  
128 recognize that a range of gender identities are possible. The meta package [45] was used to  
129 perform the meta-analyses in R, version 4.0.4 [46] (Box S1). The pooled prevalence estimates  
130 for each region were subsequently used to calibrate the mathematical model [1, 32, 33] that  
131 generated the HSV estimations.

### 132 **Model calibrations**

133 HSV-1 and HSV-2 incidence estimates were calibrated to the pooled mean prevalences using  
134 maximum likelihood, as per the previously published WHO HSV estimation model [1]. Any  
135 prevalence values of 0% and 100% were recoded as 0.1% and 99.9%, respectively, before taking  
136 logs for the likelihood equations. For the calibration, a constant force of infection,  $\lambda$ , was  
137 assumed; that is, assuming a constant incidence rate model. An additional term,  $k$ , representing  
138 the maximum proportion of individuals that can be infected, was also included and  
139 simultaneously calibrated along with  $\lambda$ . It was assumed that individuals can be infected with  
140 HSV-1 from age 0 years, and with HSV-2 from age 15 years. Calibration was done using the  
141 Solver function in Microsoft Excel. Further details and the model equations can be found in Box  
142 S3.

143 For HSV-1, single data points were included in the calibrations for the WHO South-East Asia  
144 region, due to particularly poor data availability. Sex-specific estimates were produced for the  
145 Americas and European regions as conducted previously [1], but for children (<15 years), all of  
146 female, male, and mixed data for a given age band were pooled and used for calibration for each  
147 of females and males, to avoid skewing the model calibrations by sex. For the Western Pacific,  
148 African, Eastern Mediterranean, and South-East Asia regions all of female, male, and mixed data  
149 were pooled for a given age band. Previous meta-regressions on all prevalence data for these  
150 regions showed no difference in prevalence by sex whether for Africa [38], Eastern  
151 Mediterranean [36], and Asia (combining South-East Asia and Western Pacific regions) [39]. For  
152 HSV-2, single data points were included in the calibration for the Eastern Mediterranean region,  
153 again due to poor data availability.

154 Despite the steps taken to maximize the use of available data, data were still sparse for some  
155 calibrations. The model fit for the Eastern Mediterranean region was very skewed due to low



156 availability of HSV-1 related data among children. A better fit for this region was produced by  
157 using the data for children from the Western Pacific region, due to close similarity in pooled  
158 prevalence for HSV-1 among adults in these two regions.

### 159 **Prevalence and incidence estimates**

160 Smoothed prevalence estimates by sex and 5-year age group and calibrated incidence obtained  
161 from the model fitting were then applied to demographic data by sex and 5-year age group for  
162 2020 obtained from the United Nations Population Division [47].

163 Genital infections with HSV-1 were assumed to occur only in individuals over the age of 15. All  
164 individuals under 15 years of age were assumed to have acquired the infection orally. Among  
165 individuals over 15 years of age, we used the same pooled values as in the 2016 estimates:  
166 72.4% of new infections over 15 years of age were assumed to be genital, and 36.4% oral  
167 infections (percentages add up to more than 100% due to dual oral and genital infections) [1].

168 Estimates for genital HSV-1 and HSV-2 infections were generated for individuals aged 15-49  
169 years. The percentage of individuals with genital infection due to either HSV-1 or HSV-2 was  
170 calculated by summing the separate estimates for genital HSV-1 and HSV-2, and then applying a  
171 correction factor for the estimated percentage with dual HSV-1 and HSV-2 infection (Box S3).

172 Estimates for oral HSV-1 infection were generated for individuals aged 0-49 years.

173 As in the 2016 estimation round [1], a secondary exploratory analysis was conducted where the  
174 number of individuals with HSV-1 and HSV-2 infections in each WHO region for those aged 50-  
175 99 years was estimated by applying the prevalence of each infection in individuals aged 45-49  
176 years to the population aged 50-99 years. Calculation of all estimates was done in Excel.

### 177 **Uncertainty analysis**

178 Similar to the 2016 estimates [1], 95% uncertainty intervals (UI) were computed. In brief, the  
179 force of infection,  $\lambda$ , was sampled 1000 times in Excel (keeping  $k$  constant), with standard error  
180 derived from values for  $\lambda$  calibrated to the lower and upper 95% confidence intervals (CI) for the  
181 pooled mean prevalences, while assuming a normal distribution. The percentages of individuals  
182 from age 15 years that are infected orally versus genitally were simultaneously sampled 1000  
183 times. The 95% UIs were then derived from these 1000 runs.

#### 184 **GUD estimates**

185 GUD due to HSV-2 or genital HSV-1 infection was estimated using two measures following our  
186 published method: [2] (1) the percentage and the number of people aged 15-49 years with any  
187 HSV GUD in 2020; and (2) the total number of person-days with HSV GUD among individuals  
188 aged 15-49 years old in 2020. GUD estimates were calculated by applying natural history  
189 estimates for HSV-2 and genital HSV-1 infections, i.e., the probability and duration of a first  
190 episode, the probability of a recurrence, and the length and frequency of recurrences, to the  
191 HSV-2 and HSV-1 infection estimates for 2020. These natural history estimates were derived by  
192 pooling study-level estimates obtained from a comprehensive literature review [2]. It was  
193 assumed that the total HSV-related GUD burden was equal to the sum of the burden for each of  
194 HSV-2 and genital HSV-1. Calculation of all estimates was done in Excel. Further details of how  
195 to obtain these estimates have been previously published [2].

196 The 95% UI for the percentage and number of individuals aged 15-49 years with any GUD and  
197 the total number of person-days with GUD among 15-49 years old individuals were derived as  
198 for 2016 [2]. In brief, all natural history parameters, and the calibrated force of infection (as  
199 above), were sampled 1000 times in Excel. The 95% UIs were then derived from these 1000  
200 runs.

201 **Compliance with guidelines**

202 This study complies with the Guidelines for Accurate and Transparent Health Estimates  
203 Reporting (GATHER) recommendation [48]. The complete GATHER checklist can be found in  
204 Table S1 of the Supplementary Material.

205 **Results**

206 Given that HSV-2 is the primary contributor to genital infection and recurrent GUD, the results  
207 are presented first for HSV-2.

208 **Model input and fitting**

209 In the published reviews [9-12, 27, 28, 34-40] and their update to complete the database of HSV  
210 data used for the model input, titles and abstracts of 76,972 citations were screened for relevant  
211 HSV-2 and HSV-1 data for all WHO regions. Of these, 1,228 articles reported an HSV-2 and/or  
212 HSV-1 epidemiological outcome measures (Table S2). A total of 134 articles included data that  
213 met the specific inclusion criteria for the 2020 HSV-2 estimates (list of articles in Box S4) and  
214 82 articles included data that met the specific inclusion criteria for the 2020 HSV-1 estimates  
215 (list of articles in Box S5).

216 In comparison to the 2016 estimates [1], the number of available data points improved for most  
217 of the regions (Tables S3, S4, and S5). Globally, the number of articles in 2020 surpassed that of  
218 2016. Specifically, the number of articles on HSV-2 increased from 88 to 134, and for HSV-1, it  
219 rose from 44 to 82 (Table S5). However, this increased availability did not necessarily translate  
220 into a larger number of represented countries in some of the regions.

221 Figure S1 shows the model fits for HSV-2 prevalence versus age for each WHO region. Overall,  
222 the model fitted well available data. These model fits were subsequently used to generate HSV-2  
223 incidence and prevalence estimates.

224 Figure S2 shows the model fits for HSV-1 prevalence versus age for each WHO region. Overall,  
225 the model fitted well available data. These model fits were subsequently used to generate HSV-1  
226 incidence and prevalence estimates.

### 227 **HSV-2 infection**

228 The number of incident HSV-2 infections globally in 2020 among individuals aged 15-49 years  
229 was estimated at 25.6 million (95% UI: 23.1-29.4 million) (Table 1). Of these, 15.6 million (95%  
230 UI: 13.8-18.0 million) infections were among females and 10.0 million (95% UI: 8.4-12.9  
231 million) among males. The African region had the highest HSV-2 incidence for both females and  
232 males at nearly 10 million infections, accounting for 38.3% of all infections. HSV-2 incidence  
233 rate decreased with age for all regions and was notably high among young adults in the African  
234 and Americas regions.

235 The number of people with prevalent HSV-2 infections globally in 2020 among individuals aged  
236 15-49 years was estimated at 519.5 million (95% UI: 464.3-611.3 million), an HSV-2 prevalence  
237 of 13.3% (95% UI: 11.9-15.6%) (Table 2). HSV-2 prevalence was higher in females (17.0%;  
238 95% UI: 14.9-20.1%) than in males (9.7%; 95% UI: 8.0-13.0%). The African region exhibited  
239 both the highest prevalence and the largest number of infected persons. In the secondary  
240 analysis, among individuals aged 50-99 years, an additional 389.1 million people were estimated  
241 to be infected worldwide (Table S6).

### 242 **Genital HSV-1 infection**

243 The number of incident genital HSV-1 infections globally in 2020 among individuals aged 15-49  
244 years was estimated at 16.8 million (95% UI: 10.6-22.4 million) (Table 3). Of these, 8.4 million  
245 (95% UI: 5.1-11.5 million) infections were among females and 8.4 million (95% UI: 5.0-11.8  
246 million) among males. The Western Pacific region had the highest incidence of genital HSV-1,  
247 with 4.8 million infections combining females and males. Genital HSV-1 incidence rate  
248 decreased with age for all regions and was notably high among young adults in the Americas and  
249 European regions.

250 The number of people with prevalent genital HSV-1 infections globally in 2020 among  
251 individuals aged 15-49 years was estimated at 376.2 million (95% UI: 235.6-483.5 million), a  
252 genital HSV-1 prevalence of 10.2% (95% UI: 6.4-13.1%) (Table 4). Globally, genital HSV-1  
253 prevalence was slightly higher in females (10.5%; 95% UI: 6.4-13.8%) than in males (9.9%;  
254 95% UI: 5.9-13.4%). The Americas region had the highest genital HSV-1 prevalence, but the  
255 Western Pacific region had the largest number of infected persons among those aged 15-49  
256 years.

### 257 **All genital HSV infections**

258 The number of incident genital HSV infections (HSV-2 and/or HSV-1) globally in 2020 among  
259 individuals aged 15-49 years was estimated at 42.4 million (95% UI: 33.7-51.8 million). The  
260 number of people with prevalent genital HSV infections (HSV-2 and/or HSV-1) globally in 2020  
261 among individuals aged 15-49 years was estimated at 846.1 million (95% UI: 661.1-1034.2  
262 million).

### 263 **HSV-2 and HSV-1 GUD**

264 The number of individuals 15 to 49 years of age with at least one HSV-2 GUD episode in 2020  
265 was estimated at 187.9 million (95% UI: 116.0-291.8 million), a prevalence of 4.8% (95% UI:  
266 3.0-7.5%) (Table 5). Globally, HSV-2 GUD prevalence was considerably higher in females (6.2;  
267 95% UI: 3.8-9.6%) than in males (3.5%; 95% UI: 2.2-5.8%). The total sum of GUD person-days  
268 was estimated at 8,675 million (95% UI: 5,632-15,068 million) (Table S7). The African region  
269 had both the highest HSV-2 GUD prevalence and the largest number of HSV-2 GUD person-  
270 days.

271 The number of individuals 15 to 49 years of age with at least one HSV-1 GUD episode in 2020  
272 was estimated at 16.7 million (95% UI: 9.3-25.2 million), a prevalence of 0.5% (95% UI: 0.3-  
273 0.7%) (Table 5). The total sum of GUD person-days was estimated at 166 million (95% UI: 98-  
274 562 million) (Table S7). The Americas region had the highest HSV-1 GUD prevalence and the  
275 Western Pacific region had the largest number of HSV-1 GUD person-days.

276 The number of individuals 15 to 49 years of age with at least one HSV-2 or HSV-1 GUD episode  
277 in 2020 was estimated to be 204.6 (95% UI: 132.3-306.5) million (Table 5). The total number of  
278 person-days with GUD was estimated at 8,841 (95% UI: 5,795-15,425) (Table S7).

### 279 **All and only oral HSV-1 infections**

280 Number of new (incident) HSV-1 infections globally in 2020 at any site (oral and genital) among  
281 individuals aged 0-49 years was estimated at 122.2 million (95% UI: 116.2-128.6 million) (Table  
282 S8). The African region had the highest HSV-1 incidence at nearly 40 million infections. HSV-1  
283 incidence rate decreased with age, most notably in regions where prevalence reached saturation  
284 at younger ages such as the African and Eastern Mediterranean regions (Table S8 and Figure  
285 S1).

286 The number of people with prevalent HSV-1 infections globally in 2020 at any site (oral and  
287 genital) among individuals aged 0-49 years was estimated at 3,779.1 million (95% UI: 3,510.3-  
288 3,921.6 million), a prevalence of 64.2% (95% UI: 59.7-66.7%) (Table S9). The African had the  
289 highest prevalence, but the Western Pacific region had the largest number of HSV-1 infected  
290 persons. In the secondary analysis among individuals aged 50-99 years, an additional 1,523.6  
291 million people were estimated to be infected worldwide (Table S6).

292 Global prevalence of oral HSV-1 infection in 2020 among individuals aged 0-49 years was  
293 estimated at 58.6% (95% UI: 53.5-62.1%) (Table S10). A total of 3,448.9 million (95% UI:  
294 3,144.9-3,655.2 million) people aged 0-49 years were estimated to be orally infected worldwide.  
295 The African region had the highest oral HSV-1 prevalence.

## 296 **Discussion**

297 In 2020, we estimated that 26 million people aged 15 to 49 years acquired a new HSV-2  
298 infection, 520 million people were living with an HSV-2 infection, and 188 million people had at  
299 least one episode of GUD caused by HSV-2. Additionally, in 2020, 17 million people aged 15 to  
300 49 years acquired a new genital HSV-1 infection through sexual transmission, 376 million  
301 people were living with genital HSV-1 infection, and 17 million people had at least one episode  
302 of GUD caused by HSV-1. Notably, sexual transmission accounted for only a portion of all  
303 HSV-1 infections. In total, two-thirds of the global population aged 0-49 years, or nearly 4  
304 billion people, were infected (mostly orally) with HSV-1 in 2020, with over 120 million  
305 individuals newly infected in this year.

306 The estimates for genital infection, and particularly for GUD, are higher for HSV-2 than for  
307 HSV-1. Almost all HSV-2 acquisitions are sexually transmitted and occur genitally, while the  
308 majority of HSV-1 acquisitions are not genitally acquired. Most HSV-1 infections are acquired

309 orally in childhood, although an increasing number are being acquired through sexual activity in  
310 adolescence and adulthood [26-28, 35]. In addition, HSV-1 genital tract infection is much less  
311 likely to recur compared to HSV-2 infection [4], further reducing the relative contribution of  
312 HSV-1 to GUD, even in the presence of numerous genital HSV-1 infections.

313 HSV-2 global prevalence was virtually equal in the 2016 and 2020 estimation rounds (Table S5).

314 Considering the shifts in the underlying demography during this time (increase in global average  
315 age and changing proportion of the global population in each region [47]), HSV-2 prevalence,  
316 adjusted for the demographic trends, appears to be slowly declining, as indicated also by meta-  
317 regression and modeling analyses applied on prevalence data [10-12, 34, 49]. This decline may  
318 reflect less risky sexual behaviour following the HIV epidemic [50-53], improved STI awareness  
319 [54], increasing access to HIV/STI services [55, 56], and/or changes in the structure of sexual  
320 networks following changes in socio-economic conditions [10].

321 The estimated number of prevalent genital HSV-1 infections is nearly two-fold higher in 2020  
322 compared to 2016 (376 versus 192 million) (Table S5). Meta-regression analyses on the data  
323 extracted through the regional systematic reviews as well as modeling analyses have also  
324 indicated increasing rates of genital HSV-1 infection and decreasing rates of oral infections in  
325 several regions [26-28, 35], suggesting an epidemiological transition for this infection from an  
326 oral to increasingly genital acquisition [26, 57, 58]. The increase in the global adult population  
327 and its average age [47] has also contributed to the higher number of prevalent genital HSV-1  
328 cases.

329 Differences in the global or regional estimates between 2016 and 2020 for both infections may  
330 also be attributed to improved data availability, specifically for capturing HSV-1 genital  
331 infections. In 2020, we had considerably more data from children in the South-East Asia region



332 and the Western Pacific region, potentially presenting a more realistic pattern of HSV-1  
333 prevalence by age in these regions. Although there was some overlap in the data used for the  
334 2016 and 2020 rounds, these inputs were sourced from different countries and diverse general  
335 populations. Caution is warranted in interpreting differences or similarity in time trends of all  
336 estimates considering the changes in input data.

337 This study has several limitations. The primary challenge in estimating HSV-1 and HSV-2  
338 prevalence and incidence lies in the availability and representativeness of the data. However, the  
339 enhancement in the 2020 round of calibrating the model based on the series of standardized and  
340 comprehensive HSV-1 and HSV-2 systematic reviews covering all global regions [9-12, 27, 28,  
341 34-40] has improved on this limitation with more data available than was used in previous  
342 rounds (although this was also partly due to an expanded time frame for including data in the  
343 2020 estimates). The challenges associated with input data underscore the need for more  
344 substantial, high quality, and representative epidemiological data pertaining to HSV infections.  
345 Some of the estimates, particularly those relating to HSV-1 genital infection, had wide 95% UIs  
346 due to limited input data. HSV-1 prevalence data among children remain very limited, but these  
347 data are critical for accurate and precise estimates of HSV-1 genital infection rates. Adults can be  
348 infected genitally only if they were not infected orally during childhood [26]. The proportion of  
349 incident HSV-1 infections that were estimated to be genital versus oral in adulthood was based  
350 on pooled data from only four available longitudinal studies, all of which were from the United  
351 States of America and based only on symptomatic infection incidence [1, 59-62]. The estimate  
352 for this proportion may not be representative of its value in other countries or of asymptomatic  
353 infection.

354 The force of infection was assumed constant by age, but the force of infection was only applied  
355 to those still susceptible to infection thereby effectively allowing incidence rate to decrease with  
356 age. The model was also calibrated for the maximum proportion that can be infected in addition  
357 to the force of infection. This ensured that prevalence saturates below 100% where indicated by  
358 prevalence data.

359 The model was designed to provide estimates only for those aged under 50 years, as this age  
360 group is the focus of WHO programs for sexual transmission of infection and reproductive health  
361 outcomes, and to align HSV estimates with WHO estimates for other STIs [63-65]. Prevalence  
362 estimates were additionally calculated in a secondary exploratory analysis for those aged above  
363 50 years. However, these estimates were based on simplifying assumptions due to very limited  
364 prevalence data for those aged above 50 years. No incidence estimates could be generated, and  
365 no uncertainty bounds were incorporated for these prevalence estimates due to the simplifying  
366 assumptions in generating them.

367 In conclusion, HSV infections are widely prevalent in all global regions, leading to a significant  
368 burden of GUD with repercussions on psychosocial, sexual, and reproductive health, neonatal  
369 transmission, and HIV transmission. However, hardly any specific programs for HSV prevention  
370 and control exist, even in resource-rich countries [66, 67], partly due to the lack of tools to  
371 address such highly prevalent, often asymptomatic, and incurable infections on a population  
372 level. Available prevention modalities, including condoms and antiviral therapy, are insufficient  
373 to control infection transmission and have, at best, had a modest population impact in reducing  
374 incidence rates. There is a critical need for HSV prophylactic and therapeutic vaccines as a  
375 strategic approach to control transmission and to curb the disease and economic burdens of these  
376 infections [68-70].

377 **List of abbreviations**

CI	Confidence intervals
GATHER	Guidelines for Accurate and Transparent Health Estimates Reporting
GUD	Genital ulcer disease
HSV	Herpes simplex virus
HSV-1	Herpes simplex virus type 1
HSV-2	Herpes simplex virus type 2
UI	Uncertainty interval
WHO	World Health Organization

378

379 **Supplementary Information**

380 **Additional file 1: Supplementary Material**

381

382

### 383 **Acknowledgements**

384 The authors gratefully acknowledge Professor Emeritus Rhoda Ashley Morrow from the  
385 University of Washington, for her support in assessing the quality of study diagnostic methods,  
386 and Dr. Maeve Brito De Mell from the World Health Organization for her invaluable insights  
387 during the planning and implementation of this project. The authors are also grateful to Ms.  
388 Adona Canlas for administrative support. This publication was supported by the World Health  
389 Organization (Global HIV, Hepatitis and STIs Programmes) through a grant from USAID. WHO  
390 commissioned the study, advised as required, helped with redrafts, and approved manuscript  
391 submission. MH, SM, AA, AMMO, and LJA are grateful for research support provided by the  
392 Biomedical Research Program and by the Biostatistics, Epidemiology, and the Biomathematics  
393 Research Core at Weill Cornell Medicine-Qatar. KJL thanks the National Institute for Health  
394 Research (NIHR) and the Health Protection Research Unit (HPRU) in Behavioural Science and  
395 Evaluation at the University of Bristol, in partnership with the UK Health Security Agency  
396 (UKHSA), for research support. The original systematic reviews for HSV-1 and HSV-2 were  
397 funded in part by grant numbers ARG01-0524-230321 from the Qatar Research, Development,  
398 and Innovation Council and NPRP9-040-3-008 from the Qatar National Research Fund (a  
399 member of Qatar Foundation). The authors alone are responsible for the views expressed in this  
400 article and they do not necessarily represent the views, decisions or policies of the institutions  
401 with which they are affiliated, including the NHS, the NIHR, the Department for Health and  
402 Social Care, the UKHSA, and the WHO.

### 403 **Data Availability Statement**

404 This mathematical modeling study is based on data that are publicly available. Data is provided  
405 within the manuscript or supplementary information files. No Institutional Review Board  
406 clearance was required to use these data.

#### 407 **Authors' Contributions**

408 MH, SM, AA, and AMMO conducted the literature searches, data extraction, data synthesis, and  
409 meta-analyses. KJL conducted the stages of estimates calculation and contributed to writing of  
410 the first draft. MH and LJA wrote the first draft of the manuscript. SLG and JR provided input  
411 and guidance at all stages. All authors contributed to discussion and interpretation of the results,  
412 editing of the article, and have read and approved the final manuscript.

#### 413 **Conflict of interest**

414 MH, SM, AA, AMMO, SLG, JR, and LJA declare no competing interests. KJL reports grants  
415 from WHO during the conduct of the study and outside the submitted work. KJL reports a grant  
416 from GSK outside the submitted work.

#### 417 **Ethics approval and consent to participate**

418 Not applicable.

#### 419 **Consent for publication**

420 Not applicable.

421

422

423

424

425

426

427

428

429 **Table 1.** Global and regional estimates of the number and percentage of the population aged 15-49 years with incident HSV-2 infection in 2020, by  
 430 age and sex.

Sex	WHO region	Number of people with incident HSV-2 infection in millions (population incidence, %) by age group								
		15-19 years	20-24 years	25-29 years	30-34 years	35-39 years	40-44 years	45-49 years	All ages	
		N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (95% UI <sup>a</sup> )	% (95% UI <sup>b</sup> )
Females	AFR	1.9 (3.2)	1.3 (2.6)	0.9 (2.2)	0.7 (1.8)	0.5 (1.5)	0.3 (1.2)	0.2 (1.0)	5.8 (5.1-6.5)	2.2 (1.9-2.4)
	AMR	0.5 (1.3)	0.5 (1.2)	0.4 (1.1)	0.4 (1.0)	0.4 (1.0)	0.3 (0.9)	0.3 (0.8)	2.7 (2.0-3.5)	1.1 (0.8-1.4)
	EMR	0.1 (0.2)	0.1 (0.2)	<0.1 <sup>c</sup> (0.2)	0.1 <sup>c</sup> (0.2)	<0.1 <sup>c</sup> (0.2)	<0.1 <sup>c</sup> (0.2)	<0.1 <sup>c</sup> (0.2)	0.3 (0.1-1.0)	0.2 (0.0-0.6)
	EUR	0.1 (0.6)	0.1 (0.6)	0.2 (0.6)	0.2 (0.5)	0.2 (0.5)	0.2 (0.5)	0.2 (0.5)	1.1 (0.7-1.7)	0.5 (0.3-0.8)
	SEAR	0.5 (0.6)	0.5 (0.5)	0.4 (0.5)	0.4 (0.5)	0.4 (0.5)	0.3 (0.5)	0.3 (0.5)	2.7 (2.1-3.5)	0.5 (0.4-0.7)
	WPR	0.4 (0.7)	0.4 (0.7)	0.4 (0.7)	0.5 (0.6)	0.4 (0.6)	0.4 (0.6)	0.4 (0.6)	2.9 (1.7-5.0)	0.6 (0.4-1.1)
	Overall	3.4 (1.2)	2.8 (1.0)	2.4 (0.9)	2.2 (0.7)	1.8 (0.7)	1.5 (0.6)	1.4 (0.6)	15.6 (13.8-18.0)	0.8 (0.7-0.9)
Males	AFR	1.1 (1.9)	0.9 (1.7)	0.7 (1.5)	0.5 (1.4)	0.4 (1.2)	0.3 (1.1)	0.2 (1.0)	4.0 (3.3-5.0)	1.5 (1.2-1.9)
	AMR	0.3 (0.7)	0.3 (0.6)	0.3 (0.6)	0.2 (0.6)	0.2 (0.6)	0.2 (0.6)	0.2 (0.5)	1.6 (1.1-2.1)	0.6 (0.4-0.8)
	EMR	0.1 (0.2)	0.1 (0.2)	0.1 (0.2)	0.1 (0.2)	0.1 (0.2)	<0.1 <sup>c</sup> (0.2)	<0.1 <sup>c</sup> (0.2)	0.4 (0.2-0.8)	0.2 (0.1-0.4)
	EUR	0.1 (0.3)	0.1 (0.3)	0.1 (0.3)	0.1 (0.3)	0.1 (0.3)	0.1 (0.3)	0.1 (0.3)	0.7 (0.4-1.2)	0.3 (0.2-0.5)
	SEAR	0.3 (0.3)	0.3 (0.3)	0.3 (0.3)	0.2 (0.3)	0.2 (0.3)	0.2 (0.3)	0.2 (0.3)	1.6 (1.0-2.4)	0.3 (0.2-0.4)
	WPR	0.2 (0.4)	0.2 (0.4)	0.3 (0.4)	0.3 (0.4)	0.2 (0.3)	0.2 (0.3)	0.3 (0.3)	1.7 (0.7-4.2)	0.4 (0.1-0.9)
	Overall	2.0 (0.6)	1.8 (0.6)	1.6 (0.5)	1.4 (0.5)	1.2 (0.4)	1.0 (0.4)	0.9 (0.4)	10.0 (8.4-12.9)	0.5 (0.4-0.6)
Both	Global	5.5 (0.9)	4.6 (0.8)	4.0 (0.7)	3.6 (0.6)	3.0 (0.6)	2.5 (0.5)	2.3 (0.5)	25.6 (23.1-29.4)	0.7 (0.6-0.8)

431 Abbreviations: AFR = African Region, AMR = Region of the Americas, EMR = Eastern Mediterranean Region, EUR = European Region, HSV = Herpes simplex virus, SEAR = South-East Asia region, UI = Uncertainty interval, WHO = World Health  
 432 Organization, WPR = Western Pacific Region.

433 <sup>a</sup> 95% UI of the total number of infected people in millions.

434 <sup>b</sup> 95% UI of percentage incidence.

435 <sup>c</sup> Numbers are <50,000 but ≥10,000.

436 Numbers (N) are the estimated number of people newly infected with HSV-2 during 2020. Numbers do not always sum exactly to the totals due to rounding.

437 Incidences (%) are the percentage of infected people in the age-, sex-, and region-specific population.

438 Regions are per World Health Organization definitions.

439  
440

**Table 2.** Global and regional estimates of the number and percentage of the population aged 15-49 years with prevalent HSV-2 infection in 2020, by age and sex.

Sex	WHO region	Number of people with prevalent HSV-2 infection in millions (population prevalence, %) by age group								
		15-19 years	20-24 years	25-29 years	30-34 years	35-39 years	40-44 years	45-49 years	All ages	
		N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (95% UI <sup>a</sup> )	% (95% UI <sup>b</sup> )
Females	<b>AFR</b>	10.3 (19.3)	16.2 (33.6)	19.2 (45.3)	20.4 (55.0)	20.0 (63.0)	18.0 (69.5)	15.7 (74.9)	119.8 (99.8-141.8)	44.4 (37.0-52.5)
	<b>AMR</b>	2.5 (7.2)	4.9 (13.4)	7.3 (19.1)	9.1 (24.4)	10.6 (29.4)	11.4 (34.1)	12.0 (38.4)	57.8 (42.2-77.4)	22.6 (16.5-30.2)
	<b>EMR</b>	0.3 (0.9)	0.5 (1.8)	0.7 (2.6)	0.9 (3.4)	1.0 (4.2)	1.0 (5.0)	1.0 (5.8)	5.5 (1.4-19.1)	3.0 (0.8-10.5)
	<b>EUR</b>	0.8 (3.3)	1.5 (6.1)	2.5 (8.9)	3.8 (11.6)	4.7 (14.3)	5.4 (16.8)	6.1 (19.3)	24.7 (15.2-39.3)	11.7 (7.2-18.6)
	<b>SEAR</b>	2.4 (3.1)	4.7 (5.8)	6.6 (8.4)	8.4 (11.0)	9.8 (13.5)	10.4 (15.9)	10.8 (18.3)	53.1 (40.2-69.1)	10.0 (7.6-13.0)
	<b>WPR</b>	2.0 (4.0)	4.1 (7.5)	6.7 (10.8)	10.9 (14.0)	11.1 (17.2)	12.5 (20.2)	17.1 (23.1)	64.5 (35.8-116.4)	14.0 (7.8-25.3)
	<b>Overall</b>	18.2 (6.2)	32.0 (11.1)	43.2 (15.0)	53.5 (18.2)	57.1 (21.4)	58.7 (24.2)	62.7 (26.5)	325.5 (284.9-383.0)	17.0 (14.9-20.1)
Males	<b>AFR</b>	5.8 (10.7)	9.5 (19.5)	11.6 (27.4)	12.7 (34.5)	12.7 (41.0)	11.8 (46.8)	10.6 (52.0)	74.8 (59.0-97.0)	27.7 (21.9-36.0)
	<b>AMR</b>	1.3 (3.7)	2.7 (7.0)	4.0 (10.2)	4.9 (13.2)	5.7 (16.2)	6.2 (19.0)	6.5 (21.8)	31.3 (22.1-43.3)	12.2 (8.6-16.9)
	<b>EMR</b>	0.3 (1.1)	0.6 (2.0)	0.9 (3.0)	1.2 (4.0)	1.3 (4.9)	1.3 (5.8)	1.2 (6.8)	7.0 (3.0-16.0)	3.5 (1.5-8.1)
	<b>EUR</b>	0.4 (1.8)	0.9 (3.4)	1.5 (5.0)	2.2 (6.5)	2.6 (8.0)	3.0 (9.5)	3.4 (11.0)	14.0 (7.6-24.9)	6.5 (3.5-11.6)
	<b>SEAR</b>	1.4 (1.6)	2.7 (3.1)	3.9 (4.6)	4.8 (6.0)	5.6 (7.4)	5.9 (8.8)	6.2 (10.2)	30.6 (19.7-46.3)	5.4 (3.5-8.2)
	<b>WPR</b>	1.1 (2.1)	2.4 (3.9)	3.9 (5.7)	6.1 (7.5)	6.2 (9.2)	7.0 (10.9)	9.6 (12.6)	36.5 (13.8-93.3)	7.4 (2.8-18.9)
	<b>Overall</b>	10.5 (3.3)	18.8 (6.1)	25.8 (8.5)	32.0 (10.4)	34.3 (12.5)	35.3 (14.2)	37.5 (15.6)	194.1 (160.0-260.5)	9.7 (8.0-13.0)
<b>Both</b>	<b>Global</b>	28.7 (4.7)	50.8 (8.5)	69.0 (11.7)	85.5 (14.2)	91.4 (16.9)	94.0 (19.2)	100.2 (21.0)	519.5 (464.3-611.3)	13.3 (11.9-15.6)

441  
442  
443  
444  
445  
446  
447  
448

Abbreviations: AFR = African Region, AMR = Region of the Americas, EMR = Eastern Mediterranean Region, EUR = European Region, HSV = Herpes simplex virus, SEAR = South-East Asia region, UI = Uncertainty interval, WHO = World Health Organization, WPR = Western Pacific Region.  
<sup>a</sup> 95% UI of the total number of infected people in millions.  
<sup>b</sup> 95% UI of percentage prevalence.  
 Numbers (N) are the year 2020 estimated number of people living with HSV-2 infection. Numbers do not always sum exactly to the totals due to rounding.  
 Prevalences (%) are the percentage of infected people in the age-, sex-, and region-specific population.  
 Regions are per World Health Organization definitions.



449 **Table 3.** Global and regional estimates of the number and percentage of the population aged 15-49 years with incident genital HSV-1 infection in  
 450 2020, by age and sex.

Sex	WHO region	Number of people with incident genital HSV-1 infection in millions (population incidence, %) by age group								
		15-19 years	20-24 years	25-29 years	30-34 years	35-39 years	40-44 years	45-49 years	All ages	
		N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (95% UI <sup>a</sup> )	% (95% UI <sup>b</sup> )
Females	AFR	<0.1 <sup>c</sup> (0.1)	<0.1 <sup>d</sup> (0.0)	<0.1 <sup>d</sup> (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0-0.5)	0.0 (0.0-0.3)
	AMR	0.5 (1.4)	0.4 (1.1)	0.4 (0.9)	0.3 (0.8)	0.2 (0.6)	0.2 (0.5)	0.1 (0.4)	2.1 (1.4-2.6)	0.9 (0.6-1.0)
	EMR	0.2 (0.7)	0.1 (0.3)	<0.1 <sup>c</sup> (0.2)	<0.1 <sup>c</sup> (0.1)	<0.1 <sup>c</sup> (0.0)	<0.1 <sup>d</sup> (0.0)	<0.1 <sup>d</sup> (0.0)	0.4 (0.0-1.2)	0.3 (0.0-0.8)
	EUR	0.4 (1.4)	0.3 (1.1)	0.2 (0.8)	0.2 (0.6)	0.2 (0.5)	0.1 (0.4)	0.1 (0.3)	1.5 (0.9-1.9)	0.7 (0.4-0.8)
	SEAR	0.9 (1.0)	0.5 (0.6)	0.3 (0.4)	0.2 (0.2)	0.1 (0.1)	0.1 (0.1)	<0.1 <sup>c</sup> (0.1)	2.1 (0.2-3.9)	0.4 (0.0-0.8)
	WPR	0.7 (1.3)	0.5 (0.9)	0.4 (0.6)	0.3 (0.4)	0.2 (0.2)	0.1 (0.2)	0.1 (0.1)	2.3 (1.3-3.3)	0.5 (0.3-0.7)
	<b>Overall</b>	2.7 (0.9)	1.9 (0.6)	1.3 (0.5)	1.0 (0.3)	0.7 (0.3)	0.5 (0.2)	0.3 (0.1)	8.4 (5.1-11.5)	0.5 (0.3-0.6)
Males	AFR	<0.1 <sup>c</sup> (0.1)	<0.1 <sup>d</sup> (0.0)	<0.1 <sup>d</sup> (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0-0.5)	0.0 (0.0-0.3)
	AMR	0.5 (1.3)	0.4 (1.0)	0.3 (0.8)	0.3 (0.7)	0.2 (0.6)	0.2 (0.5)	0.1 (0.4)	2.0 (1.3-2.4)	0.8 (0.5-1.0)
	EMR	0.2 (0.7)	0.1 (0.3)	0.1 (0.2)	<0.1 <sup>c</sup> (0.1)	<0.1 <sup>c</sup> (0.0)	<0.1 <sup>d</sup> (0.0)	<0.1 <sup>d</sup> (0.0)	0.4 (0.0-1.3)	0.3 (0.0-0.8)
	EUR	0.3 (1.2)	0.2 (0.9)	0.2 (0.6)	0.2 (0.5)	0.1 (0.4)	0.1 (0.3)	0.1 (0.2)	1.2 (0.7-1.5)	0.5 (0.3-0.7)
	SEAR	1.0 (1.0)	0.6 (0.6)	0.3 (0.4)	0.2 (0.2)	0.1 (0.1)	0.1 (0.1)	<0.1 <sup>c</sup> (0.1)	2.3 (0.2-4.2)	0.4 (0.0-0.8)
	WPR	0.8 (1.3)	0.8 (0.9)	0.4 (0.6)	0.3 (0.4)	0.2 (0.2)	0.1 (0.2)	0.1 (0.1)	2.5 (1.4-3.5)	0.5 (0.3-0.7)
	<b>Overall</b>	2.9 (0.9)	1.9 (0.6)	1.3 (0.4)	1.0 (0.3)	0.6 (0.2)	0.4 (0.2)	0.3 (0.1)	8.4 (5.0-11.8)	0.4 (0.3-0.6)
<b>Both</b>	<b>Global</b>	5.6 (0.9)	3.8 (0.6)	2.7 (0.5)	2.0 (0.3)	1.3 (0.2)	0.9 (0.2)	0.6 (0.1)	16.8 (10.6-22.4)	0.3 (0.2-0.4)

451 Abbreviations: AFR = African Region, AMR = Region of the Americas, EMR = Eastern Mediterranean Region, EUR = European Region, HSV = Herpes simplex virus, SEAR = South-East Asia region, UI = Uncertainty interval, WHO = World Health  
 452 Organization, WPR = Western Pacific Region.

453 <sup>a</sup> 95% UI of the total number of infected people in millions.

454 <sup>b</sup> 95% UI of percentage incidence.

455 <sup>c</sup> Numbers are <50,000 but ≥10,000.

456 <sup>d</sup> Numbers are <5,000 but ≥1,000.

457 Numbers (N) are the estimated number of people newly infected with HSV-1 during 2020. Numbers do not always sum exactly to the totals due to rounding.

458 Incidences (%) are the percentage of infected people in the age-, sex-, and region-specific population.

459 Regions are per World Health Organization definitions.

460

461

462  
463

**Table 4.** Global and regional estimates of the number and percentage of the population aged 15-49 years with prevalent genital HSV-1 infection in 2020, by age and sex.

Sex	WHO region	Number of people with prevalent genital HSV-1 infection in millions (population prevalence, %) by age group								
		15-19 years	20-24 years	25-29 years	30-34 years	35-39 years	40-44 years	45-49 years	All ages	
		N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (95% UI <sup>a</sup> )	% (95% UI <sup>b</sup> )
Females	AFR	0.1 (0.2)	0.1 (0.2)	0.1 (0.2)	0.1 (0.3)	0.1 (0.3)	0.1 (0.3)	0.1 (0.3)	0.6 (0.0-9.4)	0.3 (0.0-4.4)
	AMR	1.0 (3.5)	3.5 (9.6)	5.6 (14.6)	7.0 (18.6)	7.9 (22.0)	8.3 (24.7)	8.5 (26.9)	41.7 (27.5-50.6)	17.0 (11.2-20.6)
	EMR	0.5 (1.9)	1.2 (4.3)	1.6 (5.4)	1.7 (5.9)	1.5 (6.2)	1.3 (6.3)	1.1 (6.4)	8.8 (0.4-22.5)	5.7 (0.3-14.5)
	EUR	0.7 (3.8)	2.4 (9.9)	4.1 (14.5)	5.9 (18.1)	6.8 (20.8)	7.3 (22.8)	7.7 (24.4)	35.1 (22.8-43.0)	15.9 (10.3-19.5)
	SEAR	1.8 (2.7)	5.1 (6.5)	6.9 (8.8)	7.8 (10.2)	8.1 (11.1)	7.7 (11.7)	7.2 (12.0)	44.7 (4.4-74.2)	9.3 (0.9-15.4)
	WPR	1.5 (3.6)	4.8 (8.8)	7.6 (12.2)	11.3 (14.4)	10.4 (15.9)	10.6 (16.9)	13.1 (17.5)	59.3 (35.1-80.1)	12.0 (7.1-16.2)
	Overall	5.7 (1.9)	17.2 (6.0)	25.9 (9.0)	33.8 (11.5)	34.9 (13.1)	35.3 (14.5)	37.6 (15.9)	190.3 (115.2-249.7)	10.5 (6.4-13.8)
Males	AFR	0.1 (0.2)	0.1 (0.2)	0.1 (0.2)	0.1 (0.3)	0.1 (0.3)	0.1 (0.3)	0.1 (0.3)	0.6 (0.0-9.2)	0.3 (0.0-4.3)
	AMR	1.0 (3.3)	3.3 (8.9)	5.2 (13.5)	6.5 (17.2)	7.2 (20.3)	7.4 (22.8)	7.4 (24.8)	38.0 (24.8-45.8)	15.6 (10.2-18.9)
	EMR	0.5 (1.9)	1.3 (4.3)	1.7 (5.4)	1.8 (5.9)	1.7 (6.2)	1.4 (6.3)	1.2 (6.4)	9.7 (0.6-25.0)	5.8 (0.3-14.9)
	EUR	0.6 (3.0)	2.0 (7.9)	3.4 (11.5)	4.7 (14.2)	5.3 (16.1)	5.6 (17.6)	5.8 (18.7)	27.5 (16.8-34.0)	12.4 (7.5-15.3)
	SEAR	2.0 (2.7)	5.6 (6.5)	7.5 (8.8)	8.3 (10.2)	8.5 (11.1)	8.0 (11.7)	7.3 (12.0)	47.3 (3.7-78.6)	9.3 (0.7-15.5)
	WPR	1.7 (3.6)	5.3 (8.8)	8.3 (12.2)	12.0 (14.4)	10.9 (15.9)	11.0 (16.9)	13.6 (17.5)	62.9 (38.4-84.3)	12.0 (7.3-16.1)
	Overall	5.9 (1.9)	17.7 (5.8)	26.3 (8.6)	33.4 (10.9)	33.7 (12.3)	33.5 (13.5)	35.4 (14.8)	186.0 (111.4-250.7)	9.9 (5.9-13.4)
Both	Global	11.6 (1.9)	34.9 (5.9)	52.2 (8.8)	67.2 (11.2)	68.6 (12.7)	68.8 (14.0)	73.0 (15.3)	376.2 (235.6-483.5)	10.2 (6.4-13.1)

464  
465  
466  
467  
468  
469  
470  
471

Abbreviations: AFR = African Region, AMR = Region of the Americas, EMR = Eastern Mediterranean Region, EUR = European Region, HSV = Herpes simplex virus, SEAR = South-East Asia region, UI = Uncertainty interval, WHO = World Health Organization, WPR = Western Pacific Region.  
<sup>a</sup> 95% UI of the total number of infected people in millions.  
<sup>b</sup> 95% UI of percentage prevalence.  
 Numbers (N) are the year 2020 estimated number of people living with HSV-1 infection. Numbers do not always sum exactly to the totals due to rounding.  
 Prevalences (%) are the percentage of infected people in the age-, sex-, and region-specific population.  
 Regions are per World Health Organization definitions.

472  
473**Table 5.** Global and regional estimates of number and percentage of the population aged 15-49 years with at least one episode of GUD due to HSV-2 or HSV-1 in 2020, by age and sex.

Sex	WHO region	Number of people with HSV GUD in millions (population prevalence, %) by age group								All ages	
		15-19 years	20-24 years	25-29 years	30-34 years	35-39 years	40-44 years	45-49 years	N (95% UI <sup>a</sup> )	% (95% UI <sup>b</sup> )	
		N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)			
<b>HSV-2</b>											
Females	AFR	4.0 (6.8)	6.0 (11.9)	7.0 (16.0)	7.3 (19.4)	7.1 (22.2)	6.4 (24.4)	5.6 (26.3)	43.3 (26.3-67.4)	16.1 (9.8-25.0)	
	AMR	1.0 (2.6)	1.8 (4.7)	2.7 (6.7)	3.3 (8.6)	3.8 (10.4)	4.1 (12.0)	4.3 (13.5)	20.9 (12.2-33.9)	8.2 (4.7-13.2)	
	EMR	0.1 (0.3)	0.2 (0.6)	0.3 (0.9)	0.3 (1.2)	0.4 (1.5)	0.4 (1.8)	0.3 (2.1)	2.0 (0.5-7.6)	1.1 (0.3-4.1)	
	EUR	0.3 (1.2)	0.6 (2.2)	0.9 (3.2)	1.4 (4.1)	1.7 (5.0)	1.9 (5.9)	2.2 (6.8)	8.9 (4.5-16.6)	4.2 (2.1-7.9)	
	SEAR	1.0 (1.1)	1.7 (2.1)	2.4 (3.0)	3.0 (3.9)	3.5 (4.8)	3.7 (5.6)	3.9 (6.4)	19.2 (11.2-32.0)	3.6 (2.1-6.0)	
	WPR	0.8 (1.4)	1.5 (2.6)	2.5 (3.8)	3.9 (5.0)	4.0 (6.0)	4.5 (7.1)	6.1 (8.1)	23.3 (10.6-46.6)	5.1 (2.3-10.1)	
	Overall	7.1 (2.4)	11.8 (4.1)	15.7 (5.5)	19.3 (6.5)	20.4 (7.7)	21.0 (8.6)	22.3 (9.4)	117.6 (72.0-184.1)	6.2 (3.8-9.6)	
Males	AFR	2.3 (3.8)	3.5 (6.9)	4.2 (9.7)	4.6 (12.2)	4.6 (14.4)	4.2 (16.5)	3.8 (18.3)	27.1 (15.9-43.1)	10.1 (5.9-16.0)	
	AMR	0.5 (1.3)	1.0 (2.5)	1.4 (3.6)	1.8 (4.7)	2.1 (5.7)	2.2 (6.7)	2.3 (7.7)	11.3 (6.2-19.0)	4.4 (2.4-7.4)	
	EMR	0.1 (0.4)	0.2 (0.7)	0.3 (1.1)	0.4 (1.4)	0.5 (1.7)	0.5 (2.1)	0.4 (2.4)	2.5 (1.0-6.3)	1.3 (0.5-3.2)	
	EUR	0.2 (0.6)	0.3 (1.2)	0.5 (1.8)	0.8 (2.3)	0.9 (2.8)	1.1 (3.4)	1.2 (3.9)	5.0 (2.3-10.2)	2.3 (1.0-4.7)	
	SEAR	0.6 (0.6)	1.0 (1.1)	1.4 (1.6)	1.7 (2.1)	2.0 (2.6)	2.1 (3.1)	2.2 (3.6)	11.1 (5.5-20.2)	2.0 (1.0-3.6)	
	WPR	0.5 (0.7)	0.9 (1.4)	1.4 (2.0)	2.2 (2.6)	2.2 (3.2)	2.5 (3.8)	3.4 (4.4)	13.2 (4.4-36.2)	2.7 (0.9-7.4)	
	Overall	4.1 (1.3)	7.0 (2.3)	9.4 (3.1)	11.5 (3.7)	12.3 (4.5)	12.6 (5.1)	13.4 (5.6)	70.3 (43.0-116.7)	3.5 (2.2-5.8)	
Both	Global	11.2 (1.8)	18.8 (3.2)	25.1 (4.2)	30.8 (5.1)	32.7 (6.0)	33.6 (6.8)	35.7 (7.5)	187.9 (116.0-291.8)	4.8 (3.0-7.5)	
<b>HSV-1</b>											
Females	AFR	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0-0.5)	0.0 (0.0-0.3)	
	AMR	0.4 (0.9)	0.5 (1.2)	0.4 (1.0)	0.3 (0.8)	0.2 (0.7)	0.2 (0.5)	0.1 (0.4)	2.1 (1.2-3.0)	0.8 (0.5-1.2)	
	EMR	0.2 (0.5)	0.1 (0.5)	0.1 (0.2)	0.0 (0.1)	0.0 (0.1)	0.0 (0.0)	0.0 (0.0)	0.4 (0.0-1.2)	0.3 (0.0-0.8)	
	EUR	0.3 (1.0)	0.3 (1.2)	0.3 (0.9)	0.2 (0.7)	0.2 (0.5)	0.1 (0.4)	0.1 (0.3)	1.5 (0.8-2.2)	0.7 (0.4-1.0)	
	SEAR	0.6 (0.7)	0.6 (0.7)	0.4 (0.5)	0.2 (0.3)	0.1 (0.2)	0.1 (0.1)	0.0 (0.1)	2.1 (0.2-4.1)	0.4 (0.0-0.8)	
	WPR	0.5 (0.9)	0.6 (1.0)	0.4 (0.7)	0.4 (0.4)	0.2 (0.3)	0.1 (0.2)	0.1 (0.1)	2.3 (1.2-3.6)	0.5 (0.2-0.7)	
	Overall	1.9 (0.7)	2.1 (0.7)	1.5 (0.5)	1.1 (0.4)	0.8 (0.3)	0.5 (0.2)	0.4 (0.2)	8.4 (4.7-12.5)	0.5 (0.3-0.7)	
Males	AFR	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0-0.6)	0.0 (0.0-0.3)	
	AMR	0.3 (0.9)	0.4 (1.1)	0.4 (0.9)	0.3 (0.7)	0.2 (0.6)	0.2 (0.5)	0.1 (0.4)	1.9 (1.1-2.8)	0.8 (0.5-1.1)	
	EMR	0.2 (0.5)	0.1 (0.5)	0.1 (0.2)	0.0 (0.1)	0.0 (0.1)	0.0 (0.0)	0.0 (0.0)	0.4 (0.0-1.4)	0.3 (0.0-0.8)	
	EUR	0.2 (0.8)	0.3 (1.0)	0.2 (0.7)	0.2 (0.5)	0.1 (0.4)	0.1 (0.3)	0.1 (0.2)	1.2 (0.6-1.7)	0.5 (0.3-0.8)	
	SEAR	0.7 (0.7)	0.7 (0.7)	0.4 (0.5)	0.2 (0.3)	0.1 (0.2)	0.1 (0.1)	0.0 (0.1)	2.2 (0.2-4.4)	0.4 (0.0-0.9)	
	WPR	0.6 (0.9)	0.7 (1.0)	0.5 (0.7)	0.4 (0.4)	0.2 (0.3)	0.1 (0.2)	0.1 (0.1)	2.5 (1.3-4.0)	0.5 (0.2-0.8)	
	Overall	2.0 (0.6)	2.2 (0.7)	1.5 (0.5)	1.1 (0.4)	0.7 (0.3)	0.5 (0.2)	0.3 (0.1)	8.3 (4.5-12.7)	0.4 (0.2-0.7)	
Both	Global	3.9 (0.6)	4.3 (0.7)	3.1 (0.5)	2.2 (0.4)	1.4 (0.3)	1.0 (0.2)	0.7 (0.1)	16.7 (9.3-25.2)	0.5 (0.3-0.7)	
<b>HSV-2 and HSV-1</b>											
Overall GUD	Females	9.0 (3.1)	14.0 (4.9)	17.2 (6.0)	20.4 (6.9)	21.2 (8.0)	21.5 (8.8)	22.7 (9.6)	126.0 (80.3-191.4)	6.6 (4.2-10.1)	
	Males	6.1 (1.9)	9.2 (3.0)	10.9 (3.6)	12.6 (4.1)	13.0 (4.7)	13.1 (5.3)	13.7 (5.7)	78.6 (50.2-125.2)	4.0 (2.5-6.3)	
	Both	15.2 (2.5)	23.2 (3.9)	28.1 (4.8)	33.0 (5.5)	34.2 (6.3)	34.5 (7.0)	36.4 (7.6)	204.6 (132.3-306.5)	5.3 (3.4-7.9)	

474  
475  
476  
477  
478  
479  
480

Abbreviations: AFR = African Region, AMR = Region of the Americas, EMR = Eastern Mediterranean Region, EUR = European Region, GUD = Genital ulcer disease, HSV = Herpes simplex virus, SEAR = South-East Asia region, UI = Uncertainty interval, WHO = World Health Organization, WPR = Western Pacific Region.

<sup>a</sup> 95% UI of the total number of infected people in millions.

<sup>b</sup> 95% UI of percentage prevalence.

Numbers (N) are the year 2020 estimated number of people living with genital ulcer disease caused by HSV-1 and/or HSV-2. Numbers do not always sum exactly to the totals due to rounding.

Prevalences (%) are the percentage of infected people in the age-, sex-, and region-specific population.

Regions are per World Health Organization definitions.

481 **References**

- 482 1. James C, Harfouche M, Welton NJ, Turner KM, Abu-Raddad LJ, Gottlieb SL, Looker KJ: **Herpes**  
483 **simplex virus: global infection prevalence and incidence estimates, 2016.** *Bull World Health Organ*  
484 2020, **98**(5):315-329.
- 485 2. Looker KJ, Johnston C, Welton NJ, James C, Vickerman P, Turner KME, Boily MC, Gottlieb SL: **The**  
486 **global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history**  
487 **modelling study.** *BMJ Glob Health* 2020, **5**(3):e001875.
- 488 3. Silva S, Ayoub HH, Johnston C, Atun R, Abu-Raddad LJ: **Estimated economic burden of genital herpes**  
489 **and HIV attributable to herpes simplex virus type 2 infections in 90 low- and middle-income**  
490 **countries: A modeling study.** *PLoS Med* 2022, **19**(12):e1003938.
- 491 4. Johnston C, Margaret A, Son H, Stern M, Rathbun M, Renner D, Szpara M, Gunby S, Ott M, Jing L *et al*:  
492 **Viral Shedding 1 Year Following First-Episode Genital HSV-1 Infection.** *JAMA* 2022, **328**(17):1730-  
493 1739.
- 494 5. Tronstein E, Johnston C, Huang ML, Selke S, Margaret A, Warren T, Corey L, Wald A: **Genital shedding**  
495 **of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.** *JAMA*  
496 2011, **305**(14):1441-1449.
- 497 6. Ramchandani M, Kong M, Tronstein B, Selke S, Mikhaylova A, Huang M-L, Johnston C, Corey L, Wald  
498 A: **Herpes Simplex Virus Type 1 in Tears, and Nasal and Oral Mucosa of Healthy Adults.** *Sexually*  
499 *Transmitted Diseases* 2016, **43**(12):756-760.
- 500 7. Mark KE, Wald A, Margaret AS, Selke S, Olin L, Huang M-L, Corey L: **Rapidly cleared episodes of**  
501 **herpes simplex virus reactivation in immunocompetent adults.** *Journal of Infectious Diseases* 2008,  
502 **198**(8):1141-1149.
- 503 8. Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Margaret A, Wald A, Corey L: **Frequent release**  
504 **of low amounts of herpes simplex virus from neurons: results of a mathematical model.** *Sci Transl*  
505 *Med* 2009, **1**(7):7ra16.
- 506 9. AlMukdad S, Farooqui US, Harfouche M, Aldos L, Abu-Raddad LJ: **Epidemiology of Herpes Simplex**  
507 **Virus Type 2 in Canada, Australia, and New Zealand: Systematic Review, Meta-Analyses, and**  
508 **Meta-Regressions.** *Sex Transm Dis* 2022, **49**(6):403-413.
- 509 10. AlMukdad S, Harfouche M, Wettstein A, Abu-Raddad LJ: **Epidemiology of herpes simplex virus type**  
510 **2 in Asia: A systematic review, meta-analysis, and meta-regression.** *Lancet Reg Health West Pac* 2021,  
511 **12**:100176.
- 512 11. Harfouche M, Abu-Hijleh FM, James C, Looker KJ, Abu-Raddad LJ: **Epidemiology of herpes simplex**  
513 **virus type 2 in sub-Saharan Africa: Systematic review, meta-analyses, and meta-regressions.**  
514 *EClinicalMedicine* 2021, **35**:100876.
- 515 12. Harfouche M, Maalmi H, Abu-Raddad LJ: **Epidemiology of herpes simplex virus type 2 in Latin**  
516 **America and the Caribbean: systematic review, meta-analyses and metaregressions.** *Sex Transm*  
517 *Infect* 2021, **97**(7):490-500.
- 518 13. Fisman DN: **Health related quality of life in genital herpes: a pilot comparison of measures.** *Sex*  
519 *Transm Infect* 2005, **81**(3):267-270.
- 520 14. Gupta R, Warren T, Wald A: **Genital herpes.** *Lancet* 2007, **370**(9605):2127-2137.
- 521 15. Mark H, Gilbert L, Nanda J: **Psychosocial well-being and quality of life among women newly**  
522 **diagnosed with genital herpes.** *J Obstet Gynecol Neonatal Nurs* 2009, **38**(3):320-326.
- 523 16. Mindel A, Marks C: **Psychological symptoms associated with genital herpes virus infections:**  
524 **epidemiology and approaches to management.** *CNS Drugs* 2005, **19**(4):303-312.
- 525 17. Looker KJ, Elmes JA, Gottlieb SL, Schiffer JT, Vickerman P, Turner KM, Boily M-C: **Effect of HSV-2**  
526 **infection on subsequent HIV acquisition: an updated systematic review and meta-analysis.** *The*  
527 *Lancet infectious diseases* 2017, **17**(12):1303-1316.

- 528 18. Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini Jr IM, Self SG, Corey L: **Genital herpes has**  
529 **played a more important role than any other sexually transmitted infection in driving HIV**  
530 **prevalence in Africa.** *PloS one* 2008, **3**(5):e2230.
- 531 19. Looker KJ, Welton NJ, Sabin KM, Dalal S, Vickerman P, Turner KME, Boily M-C, Gottlieb SL: **Global**  
532 **and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence:**  
533 **a population attributable fraction analysis using published epidemiological data.** *The Lancet*  
534 *Infectious Diseases* 2020, **20**(2):240-249.
- 535 20. Omori R, Nagelkerke N, Abu-Raddad LJ: **HIV and herpes simplex virus type 2 epidemiological**  
536 **synergy: misguided observational evidence? A modelling study.** *Sexually Transmitted Infections* 2018,  
537 **94**(5):372-376.
- 538 21. Higgins C, Schofield J, Tatnall F, Leigh I: **Natural history, management and complications of herpes**  
539 **labialis.** *Journal of medical virology* 1993, **41**(S1):22-26.
- 540 22. Petti S, Lodi G: **The controversial natural history of oral herpes simplex virus type 1 infection.** *Oral*  
541 *Diseases* 2019, **25**(8):1850-1865.
- 542 23. Brady RC, Bernstein DI: **Treatment of herpes simplex virus infections.** *Antiviral Res* 2004, **61**(2):73-  
543 81.
- 544 24. Fatahzadeh M, Schwartz RA: **Human herpes simplex virus infections: epidemiology, pathogenesis,**  
545 **symptomatology, diagnosis, and management.** *J Am Acad Dermatol* 2007, **57**(5):737-763; quiz 764-  
546 736.
- 547 25. Whitley R, Baines J: **Clinical management of herpes simplex virus infections: past, present, and**  
548 **future.** *F1000Research* 2018, **7**.
- 549 26. Ayoub HH, Chemaitelly H, Abu-Raddad LJ: **Characterizing the transitioning epidemiology of herpes**  
550 **simplex virus type 1 in the USA: model-based predictions.** *BMC medicine* 2019, **17**(1):57.
- 551 27. AlMukdad S, Harfouche M, Farooqui US, Aldos L, Abu-Raddad LJ: **Epidemiology of Herpes Simplex**  
552 **Virus Type 1 in Canada: Systematic Review, Meta-Analyses, and Meta-Regressions (under review).**  
553 2023.
- 554 28. Yousuf W, Ibrahim H, Harfouche M, Abu Hijleh F, Abu-Raddad L: **Herpes simplex virus type 1 in**  
555 **Europe: systematic review, meta-analyses and meta-regressions.** *BMJ Glob Health* 2020,  
556 **5**(7):e002388.
- 557 29. Pinninti SG, Kimberlin DW: **Maternal and neonatal herpes simplex virus infections.** *Am J Perinatol*  
558 2013, **30**(2):113-119.
- 559 30. Looker KJ, Magaret AS, May MT, Turner KM, Vickerman P, Newman LM, Gottlieb SL: **First estimates**  
560 **of the global and regional incidence of neonatal herpes infection.** *The Lancet Global Health* 2017,  
561 **5**(3):e300-e309.
- 562 31. Gottlieb SL, Deal CD, Giersing B, Rees H, Bolan G, Johnston C, Timms P, Gray-Owen SD, Jerse AE,  
563 Cameron CE *et al*: **The global roadmap for advancing development of vaccines against sexually**  
564 **transmitted infections: Update and next steps.** *Vaccine* 2016, **34**(26):2939-2947.
- 565 32. Looker KJ, Magaret AS, May MT, Turner KM, Vickerman P, Gottlieb SL, Newman LM: **Global and**  
566 **regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012.** *PloS one*  
567 2015, **10**(10):e0140765.
- 568 33. Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM: **Global estimates of**  
569 **prevalent and incident herpes simplex virus type 2 infections in 2012.** *PloS one* 2015, **10**(1):e114989.
- 570 34. Alareeki A, Osman AMM, Khandakji MN, Looker KJ, Harfouche M, Abu-Raddad LJ: **Epidemiology of**  
571 **herpes simplex virus type 2 in Europe: systematic review, meta-analyses, and meta-regressions.**  
572 *Lancet Reg Health Eur* 2023, **25**:100558.
- 573 35. AlMukdad S, Harfouche M, Farooqui US, Aldos L, Abu-Raddad LJ: **Epidemiology of herpes simplex**  
574 **virus type 1 and genital herpes in Australia and New Zealand: systematic review, meta-analyses and**  
575 **meta-regressions.** *Epidemiol Infect* 2023, **151**:e33.

- 576 36. Chaabane S, Harfouche M, Chemaitelly H, Schwarzer G, Abu-Raddad LJ: **Herpes simplex virus type 1**  
577 **epidemiology in the Middle East and North Africa: systematic review, meta-analyses, and meta-**  
578 **regressions.** *Sci Rep* 2019, **9**(1):1136.
- 579 37. Harfouche M, Alareeki A, Osman AMM, Alaama AS, Hermez JG, Abu-Raddad LJ: **Epidemiology of**  
580 **herpes simplex virus type 2 in the Middle East and North Africa: Systematic review, meta-analyses,**  
581 **and meta-regressions.** *J Med Virol* 2023, **95**(3):e28603.
- 582 38. Harfouche M, Chemaitelly H, Abu-Raddad LJ: **Herpes simplex virus type 1 epidemiology in Africa:**  
583 **Systematic review, meta-analyses, and meta-regressions.** *J Infect* 2019, **79**(4):289-299.
- 584 39. Khadr L, Harfouche M, Omori R, Schwarzer G, Chemaitelly H, Abu-Raddad LJ: **The Epidemiology of**  
585 **Herpes Simplex Virus Type 1 in Asia: Systematic Review, Meta-analyses, and Meta-regressions.**  
586 *Clin Infect Dis* 2019, **68**(5):757-772.
- 587 40. Sukik L, Alyafei M, Harfouche M, Abu-Raddad LJ: **Herpes simplex virus type 1 epidemiology in Latin**  
588 **America and the Caribbean: Systematic review and meta-analytcs.** *PloS one* 2019, **14**(4):e0215487.
- 589 41. Ashley RL: **Performance and use of HSV type-specific serology test kits.** *Herpes* 2002, **9**(2):38-45.
- 590 42. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J: **Performance of focus ELISA tests**  
591 **for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse**  
592 **geographical locations.** *Clin Microbiol Infect* 2004, **10**(6):530-536.
- 593 43. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR: **Introduction to Meta-Analysis.** Chichester, UK:  
594 John Wiley & Sons, Ltd; 2011.
- 595 44. Freeman MF, Tukey JW: **Transformations Related to the Angular and the Square Root.** *Ann Math*  
596 *Statist* 1950, **21**:607-611.
- 597 45. Schwarzer G: **Meta: An R package for meta-analysis.** *R news* 2007, **7**(3):40-45.
- 598 46. RStudio Team: **RStudio: Integrated Development for R.** RStudio, Inc., Boston, MA. 2015. (Available  
599 **at: <http://www.rstudio.com/>) Accessed May 10, 2021.**
- 600 47. United Nations: Department of Economic and Social Affairs Population Division: **World Population**  
601 **Prospects 2022: Summary of Results.** UN DESA/POP/2022/TR/NO. 3. (Available at:  
602 **[https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/wpp2022\\_su](https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/wpp2022_summary_of_results.pdf)**  
603 **[mmary of results.pdf](https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/wpp2022_summary_of_results.pdf)) Accessed on December 20, 2022.** In.
- 604 48. Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, Grove JT, Hogan DR, Hogan MC,  
605 Horton R *et al*: **Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER**  
606 **statement.** *The Lancet* 2016, **388**(10062):e19-e23.
- 607 49. Ayoub HH, Amara I, Awad SF, Omori R, Chemaitelly H, Abu-Raddad LJ: **Analytic Characterization**  
608 **of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950-2050.** *Open Forum Infect*  
609 *Dis* 2021, **8**(7):ofab218.
- 610 50. Hallett TB, Gregson S, Mugurungi O, Gonese E, Garnett GP: **Assessing evidence for behaviour change**  
611 **affecting the course of HIV epidemics: a new mathematical modelling approach and application to**  
612 **data from Zimbabwe.** *Epidemics* 2009, **1**(2):108-117.
- 613 51. Hallett TB, Aberle-Grasse J, Bello G, Boulos LM, Cayemittes MP, Cheluget B, Chipeta J, Dorrington R,  
614 Dube S, Ekra AK *et al*: **Declines in HIV prevalence can be associated with changing sexual behaviour**  
615 **in Uganda, urban Kenya, Zimbabwe, and urban Haiti.** *Sexually Transmitted Infections* 2006, **82** Suppl  
616 **1**:i1-8.
- 617 52. Kilian AH, Gregson S, Ndyabangi B, Walusaga K, Kipp W, Sahlmuller G, Garnett GP, Asiimwe-Okiror  
618 G, Kabagambe G, Weis P *et al*: **Reductions in risk behaviour provide the most consistent explanation**  
619 **for declining HIV-1 prevalence in Uganda.** *Aids* 1999, **13**(3):391-398.
- 620 53. Awad SF, Abu-Raddad LJ: **Could there have been substantial declines in sexual risk behavior across**  
621 **sub-Saharan Africa in the mid-1990s?** *Epidemics* 2014, **8**(0):9-17.
- 622 54. Loeber O, Reuter S, Apter D, van der Doef S, Lazdane G, Pinter B: **Aspects of sexuality education in**  
623 **Europe—definitions, differences and developments.** *Eur J Contracep Repr* 2010, **15**(3):169-176.

- 624 55. World Health Organization: **Global health sector strategy on sexually transmitted infections 2016-**  
625 **2021.** (Available at: <https://www.who.int/publications/i/item/WHO-RHR-16.09>) Accessed on  
626 **November 16, 2020.** In.
- 627 56. Wijesooriya NS, Rochat RW, Kamb ML, Turlapati P, Temmerman M, Broutet N, Newman LM: **Global**  
628 **burden of maternal and congenital syphilis in 2008 and 2012: a health systems modelling study.** *The*  
629 *Lancet Global health* 2016, **4**(8):e525-533.
- 630 57. Bernstein DI, Bellamy AR, Hook EW, 3rd, Levin MJ, Wald A, Ewell MG, Wolff PA, Deal CD, Heineman  
631 TC, Dubin G *et al*: **Epidemiology, clinical presentation, and antibody response to primary infection**  
632 **with herpes simplex virus type 1 and type 2 in young women.** *Clinical Infectious Diseases* 2013,  
633 **56**(3):344-351.
- 634 58. Whitley RJ: **Changing epidemiology of herpes simplex virus infections.** *Clin Infect Dis* 2013,  
635 **56**(3):352-353.
- 636 59. Bernstein DI, Bellamy AR, Hook EW, 3rd, Levin MJ, Wald A, Ewell MG, Wolff PA, Deal CD, Heineman  
637 TC, Dubin G *et al*: **Epidemiology, clinical presentation, and antibody response to primary infection**  
638 **with herpes simplex virus type 1 and type 2 in young women.** *Clin Infect Dis* 2013, **56**(3):344-351.
- 639 60. Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley RL, Watts DH, Berry S, Herd M, Corey L:  
640 **The acquisition of herpes simplex virus during pregnancy.** *N Engl J Med* 1997, **337**(8):509-515.
- 641 61. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE: **A prospective study of new infections**  
642 **with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group.** *N Engl J Med* 1999,  
643 **341**(19):1432-1438.
- 644 62. Mertz GJ, Ashley R, Burke RL, Benedetti J, Critchlow C, Jones CC, Corey L: **Double-blind, placebo-**  
645 **controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for**  
646 **genital herpes infection.** *J Infect Dis* 1990, **161**(4):653-660.
- 647 63. Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, Chico RM, Smolak A,  
648 Newman L, Gottlieb S *et al*: **Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence**  
649 **and incidence estimates, 2016.** *Bull World Health Organ* 2019, **97**(8):548-562P.
- 650 64. World Health Organization: **Progress Report on HIV, Viral Hepatitis and Sexually Transmitted**  
651 **Infections 2021.** Available from: <https://www.who.int/publications/i/item/9789240027077>. Accessed  
652 **on December 4, 2023.** *World Health Organization* 2021.
- 653 65. World Health Organization: **Global and regional sexually transmitted infection estimates for 2020.**  
654 **Available from** <https://www.who.int/data/gho/data/themes/topics/global-and-regional-sti-estimates>.  
655 **Accessed on December 18, 2023.** *World Health Organization* 2023.
- 656 66. Douglas JM, Berman SM: **Screening for HSV-2 Infection in STD Clinics and Beyond: A Few Answers**  
657 **But More Questions.** *Sexually Transmitted Diseases* 2009, **36**(11):729-731.
- 658 67. Johnston C, Corey L: **Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and**  
659 **Pathogenesis of Genital Tract Shedding.** *Clin Microbiol Rev* 2016, **29**(1):149-161.
- 660 68. Gottlieb SL, Giersing B, Boily MC, Chesson H, Looker KJ, Schiffer J, Spicknall I, Hutubessy R, Broutet  
661 N, Group WHVIMMW: **Modelling efforts needed to advance herpes simplex virus (HSV) vaccine**  
662 **development: Key findings from the World Health Organization Consultation on HSV Vaccine**  
663 **Impact Modelling.** *Vaccine* 2019, **37**(50):7336-7345.
- 664 69. Gottlieb SL, Giersing BK, Hickling J, Jones R, Deal C, Kaslow DC, Group HSVVEC: **Meeting report:**  
665 **Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred**  
666 **product characteristics, March 2017.** *Vaccine* 2019, **37**(50):7408-7418.
- 667 70. Ayoub HH, Chemaitelly H, Abu-Raddad LJ: **Epidemiological Impact of Novel Preventive and**  
668 **Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses.** *Vaccines*  
669 **2020, 8**(3).
- 670

## Supplementary Material

### Table of Contents

<b>Box S1. Summary of the standardized methodology used in updating the previously conducted systematic reviews for Asia,<sup>1,2</sup> Europe,<sup>3,4</sup> Latin America and the Caribbean,<sup>5,6</sup> Middle East and North Africa,<sup>7,8</sup> sub-Saharan Africa,<sup>9,10</sup> and for Canada, Australia, New Zealand, and Pacific Island nations.<sup>11-13</sup> .....</b>	<b>2</b>
<b>Box S2. List of changes and methodological enhancements on the 2016 WHO HSV estimation round.<sup>15</sup> .....</b>	<b>3</b>
<b>Box S3. Calculation of prevalence and incidence estimates. ....</b>	<b>4</b>
<b>Table S1. Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) checklist.<sup>16</sup> .....</b>	<b>5</b>
<b>Table S2. Summary of the extracted HSV-1 and HSV-2 epidemiological outcome measures in the series of regional systematic reviews and their updates. ....</b>	<b>6</b>
<b>Box S4. List of articles on the general population from which an HSV-2 prevalence measure was extracted and included in the meta-analyses.....</b>	<b>7</b>
<b>Box S5. List of articles on the general population from which an HSV-1 prevalence measure was extracted and included in the meta-analyses.....</b>	<b>12</b>
<b>Table S3. HSV-2 prevalence measures among general populations included in the WHO HSV estimations, by region, sex, and age group. ....</b>	<b>15</b>
<b>Table S4. HSV-1 prevalence measures among general populations included in the WHO HSV estimations, by region, sex, and age group. ....</b>	<b>16</b>
<b>Table S5. Comparison of HSV estimates over the WHO HSV estimation rounds.<sup>15,17-19</sup> .....</b>	<b>17</b>
<b>Figure S1. Model fits for HSV-2 prevalence for each WHO region.....</b>	<b>18</b>
<b>Figure S2. Model fits for HSV-1 prevalence (any site; oral and genital) for each WHO region. ....</b>	<b>19</b>
<b>Table S6. Global and regional estimates of the number of people aged 50-99 years with prevalent HSV-1 or HSV-2 infection in 2020, by sex.....</b>	<b>20</b>
<b>Table S7. Global and regional estimates of GUD person-days due to HSV-2 or HSV-1 among the population aged 15-49 years in 2020, by age and sex.....</b>	<b>21</b>
<b>Table S8. Global and regional estimates of the number and percentage of the population aged 0-49 years with incident HSV-1 infection (any site, oral or genital) in 2020, by age and sex.. ....</b>	<b>212</b>
<b>Table S9. Global and regional estimates of the number and percentage of the population aged 0-49 years with prevalent HSV-1 infection (any site, oral or genital) in 2020, by age and sex.....</b>	<b>23</b>
<b>Table S10. Global and regional estimates of the number and percentage of the population aged 0-49 years with prevalent oral HSV-1 infection in 2020, by age and sex.....</b>	<b>244</b>
<b>References.....</b>	<b>255</b>



**Box S1.** Summary of the standardized methodology used in updating the previously conducted systematic reviews for Asia [1, 2], Europe [3, 4], Latin America and the Caribbean [5, 6], Middle East and North Africa [7, 8], sub-Saharan Africa [9, 10], and for Canada, Australia, New Zealand, and Pacific Island nations [11-13].

Methodology	Detailed description
<b>Data source and search strategy</b>	<ul style="list-style-type: none"> <li>- Searches were conducted up to March 30, 2022 in PubMed and Embase as well as in regional and country level databases for each of Asia, Europe, Latin America and the Caribbean, Middle East and North Africa, sub-Saharan Africa, and Canada, Australia, New Zealand, and Pacific Island nations.</li> <li>- Search strategies included exploded MeSH/Emtree terms and broad terms with no language or time restrictions.</li> </ul>
<b>Study selection and inclusion and exclusion criteria</b>	<ul style="list-style-type: none"> <li>- Search results were imported into the reference manager Endnote (Thomson Reuters, USA).</li> <li>- New citations were identified and screened.</li> <li>- Screening was performed in three stages:               <ol style="list-style-type: none"> <li>1. Duplicate publications were identified and excluded.</li> <li>2. Titles and abstracts were screened for relevant and potentially relevant publications.</li> <li>3. Full texts of relevant and potentially relevant publications were retrieved and screened for relevance.</li> </ol> </li> <li>- Inclusion criteria were any publication, including a study with a minimum sample size of 10, reporting primary data on HSV-1 and/or HSV-2 outcome measures (seroprevalence, seroincidence, proportion of HSV detection in clinically diagnosed genital ulcer disease, and proportion of HSV detection in laboratory-confirmed genital herpes).</li> <li>- Exclusion criteria were:               <ul style="list-style-type: none"> <li>o Case reports, case series, reviews, editorials, commentaries, and qualitative studies.</li> <li>o Measures reporting seroprevalence in infants aged &lt;6 months as their antibodies can be maternal in origin.</li> </ul> </li> </ul>
<b>Data extraction and data synthesis</b>	<ul style="list-style-type: none"> <li>- Extracted variables included: author(s), publication title, year(s) of data collection, year of publication, country of origin, country of survey, city, study site, study design, study sampling procedure, study population and its characteristics (e.g., sex and age), sample size, HSV outcome measures, and diagnostic assay.</li> <li>- Overall outcome measures and their stratified measures were extracted, provided the sample size in each stratum is <math>\geq 10</math>.</li> <li>- For studies including overall sample size, but no individual strata sample sizes, the sample size of each stratum was assumed equal to overall sample size divided by the number of strata in the study.</li> <li>- Missing data points for year of data collection were imputed by adjusting the year of publication using the median difference with the year of data collection in studies that reported year of data collection.</li> <li>- Age was converted into a numeric variable using the mean or the median when reported or the midpoint of the age range reported. If a range is not fully defined (i.e. &lt;25) we assumed that the range covered 10 years (i.e. 15-24) and calculated its midpoint accordingly.</li> <li>- Stratification hierarchy for HSV-1 seroprevalence in descending order of preference was:               <ul style="list-style-type: none"> <li>o Age</li> <li>o Sex</li> </ul> </li> <li>- Stratification hierarchy for HSV-2 seroprevalence in descending order of preference was:               <ul style="list-style-type: none"> <li>o Sex</li> <li>o Age</li> </ul> </li> <li>- Measures reporting any HSV-2 outcome among children &lt;15 years old were not included in the analyses.</li> <li>- Data synthesis for HSV-1 infection:               <ul style="list-style-type: none"> <li>o HSV-1 seroprevalence measures among general populations* were included in the analysis, up to the year 2020.</li> <li>o Data with a midpoint of 2004 or thereafter for the year of data collection were included due to low data availability.</li> <li>o Data with a midpoint of 1995 or thereafter for the year of data collection were included only for Africa and South-East Asia, due to particularly poor data availability.</li> <li>o Studies with undefined age range were assumed to have an age range between 15-49 years and were included for Africa, Eastern Mediterranean, South-East Asia, and Western Pacific.</li> <li>o Studies among pregnant women with undefined age range were assumed to have an age range between 18-49.</li> </ul> </li> <li>- Data synthesis for HSV-2 infection:               <ul style="list-style-type: none"> <li>o HSV-2 seroprevalence measures among general populations* were included in the analysis, up to the year 2020.</li> <li>o Data with a midpoint of 2004 or thereafter for the year of data collection were included due to low data availability.</li> <li>o Studies with undefined age range were assumed to have an age range between 15-49 years and were included for the Eastern Mediterranean and South-East Asia.</li> <li>o Studies among pregnant women with undefined age range were assumed to have an age range between 18-49.</li> <li>o One study among construction workers with an age range identified as <math>\geq 36</math> years was assumed to have an age range between 36-45 years.</li> </ul> </li> </ul>
<b>Meta-analyses</b>	<ul style="list-style-type: none"> <li>- Meta-analyses were conducted using DerSimonian-Laird random-effects models with inverse variance weighting. The variance of each outcome measure was stabilized using the Freeman-Tukey arcsine square-root transformation.</li> <li>- For each WHO region, pooled mean HSV-1 seroprevalence and pooled mean HSV-2 seroprevalence were estimated by sex (when possible) and by 5-year age group when three or more data points were available. If only two data points were available, an average weighted by sample size was calculated.</li> <li>- Heterogeneity assessment was based on three complementary metrics:               <ul style="list-style-type: none"> <li>o Cochran's Q statistic to assess existence of heterogeneity in effect size (p-value&lt;0.1 indicated heterogeneity).</li> <li>o I<sup>2</sup> heterogeneity measure to assess the percentage of between-study variation in effect size that is due to actual differences in effect size rather than chance.</li> <li>o Prediction interval to describe the distribution of true outcome measures around the pooled mean.</li> </ul> </li> </ul>

Abbreviations: HSV = Herpes simplex virus, WHO = World Health Organization

\*General populations include populations at average exposure to HSV infections in the population, such as persons included in population-based surveys, antenatal clinic attendees, and pregnant women, among others.

**Box S2.** List of changes and methodological enhancements on the 2016 WHO HSV estimation round [15].

**Preparation of the seroprevalence data for pooling**

1. Equivocal samples were included in the denominator of seroprevalence data points, rather than being excluded from both numerator and denominator, to avoid bias as such equivocal samples are likely to be sero-negative.
2. Adjustment for sensitivity and specificity for each assay type was not conducted since only studies using a robust assay were included. Moreover, assay type showed no association with HSV seroprevalence based on the series of conducted regional systematic reviews and meta-regressions for HSV-1 and HSV-2 seroprevalence [1-13].
3. Meta-analyses were conducted when three or more data points were available. Average seroprevalence (weighted by sample size) was calculated when only two data points were available.
4. Missing data points for year of data collection were imputed by adjusting the year of publication using the median difference with the year of data collection in studies that reported year of data collection.
5. For studies of pregnant women where data on age were not available, we assumed an age range of 18-49 years.

**Decisions on pooling criteria**

**HSV-1 estimates**

1. Data with a midpoint of 2004 or thereafter for the year of data collection were included due to low data availability.
2. Data with a midpoint of 1995 or thereafter for the year of data collection were included only for Africa and South-East Asia, due to particularly poor data availability.
3. Studies with undefined age range were assumed to have an age range between 15-49 years and were included for Africa, Eastern Mediterranean, South-East Asia, and Western Pacific.
4. Single data points were included in the fitting for South-East Asia, due to particularly poor data availability.
5. Sex-specific estimates were produced for the Americas and Europe as per previous estimation round (with mixed-sex estimates for the other regions), except for children (<15 years), where mixed-sex pooled mean estimates were calculated for a given age band. These combined estimates were used in the fitting for each of females and males, to avoid the few data points for children by sex skewing the model fits by sex.
6. No sex specific estimates were calculated for Africa, Eastern Mediterranean region, South-East Asia, and Western Pacific since previous systematic reviews and meta-regressions showed no difference in seroprevalence by sex for these regions [2, 7, 10, 13].

**HSV-2 estimates**

1. Data with a midpoint of 2004 or thereafter for the year of data collection were included due to low data availability.
2. Studies with undefined age range were assumed to have an age range between 15-49 years and were included for Eastern Mediterranean and South-East Asia.
3. Single data points were included in the fitting for Eastern Mediterranean, due to particularly poor data availability.

Abbreviations: HSV = Herpes simplex virus, WHO = World Health Organization

### Box S3. Calculation of prevalence and incidence estimates.

Pooled mean herpes simplex virus (HSV) seroprevalence values were used to calibrate HSV-1 and HSV-2 incidence using a constant incidence rate model. This model additionally included a term representing the maximum proportion of individuals that can be infected which was simultaneously calibrated. This term allows seroprevalence to saturate at a low or moderate value if this is indicated by the pooled seroprevalence values, for example as a consequence of lower incidence at older age. The model equation was as follows:

$$F(a) = k * (1 - e^{(-\lambda * a)})$$

where  $F(a)$  is the proportion of individuals (sero)positive at age  $a$  in years (i.e., with prevalent HSV-1 or HSV-2 infection),  $k$  is the maximum proportion of individuals that can be infected and  $\lambda$  is the force of infection per year. We assumed that individuals can be infected with HSV-1 from age 0 years, and with HSV-2 from age 12 years, and adjusted the above equation as follows for HSV-2:

$$F(a) = k * (1 - e^{(-\lambda * (a-12))})$$

Fitting was done by using the Solver function in Excel to find those values of  $k$  and  $\lambda$  which maximized the (Bernoulli likelihood) value of:

$$\ln \prod_a [F(a)^{S(a) * P(a)} * (1 - F(a))^{S(a) * (1-P(a))}]$$

where  $a$  is the mid-point of each 5-year age group,  $S(a)$  is the total sample size (from summing across all studies), and  $P(a)$  is the pooled seroprevalence.

From the model fits we obtained smoothed seroprevalence estimates by sex and 5-year age group. Using demographic data for 2020 by sex and 5-year age group obtained from the United Nations Population Division [14], and assuming a uniform distribution for population size within each 5-year age group, we multiplied seroprevalence estimates at each single year of age by regional population sizes to obtain estimates for the number of people with prevalent HSV-1 and HSV-2 infection by World Health Organization (WHO) region in 2020. The estimated number of new (incident) cases of infection at each single year of age,  $I(a)$ , was calculated as:

$$I(a) = (k - F(a)) * \lambda * N(a)$$

where  $N(a)$  is the total number of individuals (i.e., regional population size) at age  $a$ .

The percentage of people with genital infection due to either HSV-1 or HSV-2 was calculated using the following formula to correct for the estimated percentage with both HSV-2 and genital HSV-1 infection:

$$\% \text{ with any genital HSV infection} = [(\% \text{ with HSV-2 infection} + \% \text{ with genital HSV-1 infection})] - (\% \text{ with HSV-2 infection} * \% \text{ with genital HSV-1 infection})$$

Calculations were done for each single year of age separately by WHO region and sex. These percentages were then applied to demographic data for 2020 [14] and summed.

#### Uncertainty bounds

We computed 95% uncertainty intervals (UI) on the number of individuals with prevalent HSV-1 and HSV-2 infection in 2020, as a function of the uncertainty in the underlying seroprevalence data. First, we recalibrated the force of infection,  $\lambda$ , to the upper confidence bounds of each region-, age-, and sex-specific pooled HSV-1 or HSV-2 seroprevalence value, keeping  $k$  constant. We then repeated this for the lower confidence bounds of each pooled seroprevalence value. Next, we sampled the log force of infection using the log fitted force of infection and the standard error of the log fitted force of infection by sex and WHO region, assuming a normal distribution. The proportion of individuals from age 15 years that are infected orally and the proportion that are infected genitally among those with incident HSV-1 infection were also simultaneously sampled, again using the log odds and standard error of the log odds from the results of the meta-analysis for these proportions [14]. Repeating this 1000 times, the resulting set of 1000 estimates was then sorted from low to high for each estimate, sex, and region of interest and the 2.5 and 97.5 percentiles taken to represent the lower and upper uncertainty bounds.

**Table S1.** Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) checklist.[16]

Item #	Checklist item	Reported on page #
<b>Objectives and funding</b>		
1	Define the indicator(s), populations (including age, sex, and geographic entities), and time period(s) for which estimates were made.	Introduction section
2	List the funding sources for the work.	Title page
<b>Data Inputs</b>		
For all data inputs from multiple sources that are synthesized as part of the study:		
3	Describe how the data were identified and how the data were accessed.	Methods: Systematic reviews, data extraction and synthesis, and meta-analyses section; Box S1
4	Specify the inclusion and exclusion criteria. Identify all ad-hoc exclusions.	Methods: Systematic reviews, data extraction and synthesis, and meta-analyses section; Box S1
5	Provide information on all included data sources and their main characteristics. For each data source used, report reference information or contact name/institution, population represented, data collection method, year(s) of data collection, sex and age range, diagnostic criteria or measurement method, and sample size, as relevant.	Tables S1- S3; Box S4 and S5
6	Identify and describe any categories of input data that have potentially important biases (e.g., based on characteristics listed in item 5).	Box S2
For data inputs that contribute to the analysis but were not synthesized as part of the study:		
7	Describe and give sources for any other data inputs.	Box S3
For all data inputs:		
8	Provide all data inputs in a file format from which data can be efficiently extracted (e.g., a spreadsheet rather than a PDF), including all relevant meta-data listed in item 5. For any data inputs that cannot be shared because of ethical or legal reasons, such as third-party ownership, provide a contact name or the name of the institution that retains the right to the data.	Tables S1- S3; Box S4 and S5
<b>Data analysis</b>		
9	Provide a conceptual overview of the data analysis method. A diagram may be helpful.	Methods: Population-based estimation for HSV-1 and HSV-2 infections section
10	Provide a detailed description of all steps of the analysis, including mathematical formulae. This description should cover, as relevant, data cleaning, data pre-processing, data adjustments and weighting of data sources, and mathematical or statistical model(s).	Box S3
11	Describe how candidate models were evaluated and how the final model(s) were selected.	NA
12	Provide the results of an evaluation of model performance, if done, as well as the results of any relevant sensitivity analysis.	NA
13	Describe methods for calculating uncertainty of the estimates. State which sources of uncertainty were, and were not, accounted for in the uncertainty analysis.	Methods: Population-based estimation for HSV-1 and HSV-2 infections section; Box S3
14	State how analytic or statistical source code used to generate estimates can be accessed.	Box S3
<b>Results and Discussion</b>		
15	Provide published estimates in a file format from which data can be efficiently extracted.	Tables 1-5; Tables S5-S7
16	Report a quantitative measure of the uncertainty of the estimates (e.g. uncertainty intervals).	Tables 1-5; Tables S5-S7
17	Interpret results in light of existing evidence. If updating a previous set of estimates, describe the reasons for changes in estimates.	Results section; Discussion section
18	Discuss limitations of the estimates. Include a discussion of any modelling assumptions or data limitations that affect interpretation of the estimates.	Discussion section

Abbreviations: HSV = Herpes simplex virus, NA: Not Applicable.

**Table S2.** Summary of the extracted HSV-1 and HSV-2 epidemiological outcome measures in the series of regional systematic reviews and their updates.

Region	Screened citations for HSV-1 and HSV-2	Previously extracted relevant publications in the regional systematic reviews	Newly extracted relevant publications in the updates of the systematic reviews	Extracted epidemiological outcome measures
Asia	16,375	222	20	<ul style="list-style-type: none"> <li>• 26 overall HSV-2 seroincidence measures</li> <li>• 66 overall HSV-1 seroprevalence measures yielding 204 stratified measures</li> <li>• 283 overall HSV-2 seroprevalence measures yielding 697 stratified measures</li> <li>• 9 overall proportions of HSV-1 detection in GUD cases</li> <li>• 15 overall proportions of HSV-2 detection in GUD cases yielding 16 stratified proportions</li> <li>• 26 overall proportions of HSV-1 detection in genital herpes cases yielding 27 stratified proportions</li> <li>• 43 overall proportions of HSV-2 detection in genital herpes cases yielding 46 stratified proportions</li> </ul>
Africa	24,474	255	19	<ul style="list-style-type: none"> <li>• 95 overall HSV-2 seroincidence measures</li> <li>• 49 overall HSV-1 seroprevalence measures yielding 76 stratified measures</li> <li>• 352 overall HSV-2 seroprevalence measures yielding 811 stratified measures</li> <li>• 19 overall proportions of HSV-1 detection in GUD cases yielding 32 stratified proportions</li> <li>• 26 overall proportions of HSV-2 detection in GUD cases</li> <li>• 8 overall proportions of HSV-1 detection in genital herpes cases</li> <li>• 9 overall proportions of HSV-2 detection in genital herpes cases yielding 11 stratified proportions</li> </ul>
Canada, Australia, New Zealand, and Pacific Islands	3,173	90	55	<ul style="list-style-type: none"> <li>• 2 overall HSV-1 seroincidence measures</li> <li>• 7 overall HSV-2 seroincidence measures</li> <li>• 61 overall HSV-1 seroprevalence measures yielding 106 stratified seroprevalence measures</li> <li>• 37 overall HSV-2 seroprevalence measures yielding 99 stratified seroprevalence measures</li> <li>• 5 overall proportions of HSV-1 detection in GUD cases</li> <li>• 5 overall proportions of HSV-2 detection in GUD cases</li> <li>• 17 overall proportions of HSV-1 detection in genital herpes cases yielding 52 stratified proportions</li> <li>• 16 overall proportions of HSV-2 detection in genital herpes cases yielding 46 stratified proportions</li> </ul>
Europe	19,153	353	15	<ul style="list-style-type: none"> <li>• 1 overall HSV-1 seroincidence measure</li> <li>• 14 overall HSV-2 seroincidence measures</li> <li>• 198 overall HSV-1 seroprevalence measures yielding 648 stratified measures</li> <li>• 302 overall HSV-2 seroprevalence measures yielding 822 stratified measures</li> <li>• 8 overall proportions of HSV-1 detection in GUD cases</li> <li>• 17 overall proportions of HSV-2 detection in GUD cases yielding 19 stratified proportions</li> <li>• 70 overall proportions of HSV-1 detection in genital herpes cases yielding 180 stratified proportions</li> <li>• 76 overall proportions of HSV-2 detection in genital herpes cases yielding 201 stratified proportions</li> </ul>
Middle East and North Africa	5,320	52	8	<ul style="list-style-type: none"> <li>• 62 overall HSV-1 seroprevalence measures yielding 112 stratified measures</li> <li>• 60 overall HSV-2 seroprevalence measures yielding 131 stratified measures</li> <li>• 1 overall proportion of HSV-1 detection in GUD cases</li> <li>• 1 overall proportion of HSV-2 detection in GUD cases</li> <li>• 1 overall proportion of HSV-1 detection in genital herpes cases</li> <li>• 3 overall proportions of HSV-2 detection in genital herpes cases yielding 6 stratified proportions</li> </ul>
Latin America and the Caribbean	8,477	133	6	<ul style="list-style-type: none"> <li>• 13 overall HSV-2 seroincidence measures</li> <li>• 47 overall HSV-1 seroprevalence measures yielding 73 stratified measures</li> <li>• 167 overall HSV-2 seroprevalence measures yielding 410 stratified measures</li> <li>• 18 overall proportions of HSV-1 detection in GUD cases</li> <li>• 7 overall proportions of HSV-2 detection in GUD cases</li> <li>• 8 overall proportions of HSV-1 detection in genital herpes cases</li> <li>• 10 overall proportion of HSV-2 detection in genital herpes cases</li> </ul>

Abbreviations: HSV = Herpes simplex virus, GUD = Genital ulcer disease.

**Box S4.** List of articles on the general population from which an HSV-2 prevalence measure was extracted and included in the meta-analyses.

1. Abbai NS, Govender S, Nyirenda M. Herpes simplex virus-2 infections in pregnant women from Durban, South Africa: prevalence, risk factors and co-infection with HIV-1. *Southern African Journal of Infectious Diseases* 2018.
2. Abdool Karim Q, Kharsany AB, Leask K, et al. Prevalence of HIV, HSV-2 and pregnancy among high school students in rural KwaZulu-Natal, South Africa: a bio-behavioural cross-sectional survey. *Sex Transm Infect* 2014; 90(8): 620-6.
3. Abul-Razak SHH, Abbas AA-D, Hwaid AH, Wasan AM, Fadeel ZG. Seroprevalence of Anti- Herpes Simplex Virus Type2 IgG, IgM Antibodies Among Pregnant Women in Diyala Province. *Diyala Journal of Medicine* 2013; 5(1): 36-43.
4. Achilles SL, Mhlanga F, Dezzutti CS, et al. Differences in genital tract immune cell populations and innate cervicovaginal fluid anti-HIV activity among women from Zimbabwe and the United States. *AIDS Research and Human Retroviruses* 2016; 32(Supplement 1): 78.
5. Adamson PC, Krupp K, Freeman AH, Klausner JD, Reingold AL, Madhivanan P. Prevalence & correlates of primary infertility among young women in Mysore, India. *Indian Journal of Medical Research* 2011; 134(10): 440-6.
6. Akinyi B, Odhiambo C, Otieno F, et al. Prevalence, incidence, and correlates of HSV-2 infection in an HIV incidence adolescent and adult cohort study in western Kenya. *PloS one* 2017; 12(6): e0178907.
7. Al-Hakami AM, Paul E, Al-Abed F, et al. Prevalence of toxoplasmosis, rubella, cytomegalovirus, and herpes (TORCH) infections among women attending the antenatal care clinic, maternity hospital in Abha, Southwestern Saudi Arabia. *Saudi Med J* 2020; 41(7): 757-62.
8. Alberts CJ, Schim van der Loeff MF, Papenfuss MR, et al. Association of Chlamydia trachomatis infection and herpes simplex virus type 2 serostatus with genital human papillomavirus infection in men: the HPV in men study. *Sex Transm Dis* 2013; 40(6): 508-15.
9. Ali MK, Hathal HD, Almoayed HA. Prevalence and diagnosis of genital herpes by immunological and molecular study *Iraqi Journal of Medical Sciences* 2018; 16(1): 4-7.
10. Alshareef SA, Eltom AM, Nasr AM, Hamdan HZ, Adam I. Rubella, herpes simplex virus type 2 and preeclampsia. *Viol J* 2017; 14(1): 142.
11. Anaedobe CG, Ajani TA. Co-infection of herpes simplex virus type 2 and HIV infections among pregnant women in Ibadan, Nigeria. *Journal of Global Infectious Diseases* 2019; 11(1): 19-24.
12. Anjulo AA, Abebe T, Hailemichael F, Mihret A. Seroprevalence and risk factors of herpes simplex virus-2 among pregnant women attending antenatal care at health facilities in Wolaita zone, Ethiopia. *Viol J* 2016; 13: 43.
13. Arama V, Cercel AS, Vladareanu R, et al. Type-specific herpes simplex virus-1 and herpes simplex virus-2 seroprevalence in Romania: comparison of prevalence and risk factors in women and men. *International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases* 2010; 14 Suppl 3: e25-31.
14. Asgari S, Chamani-Tabriz L, Asadi S, et al. HSV-2 seroepidemiology and risk factors among Iranian women: A time to new thinking. *Iranian Red Crescent Medical Journal* 2011; 13(11): 818-23.
15. Austrian K, Hewett PC, Soler-Hampejsek E, Bozzani F, Behrman JR, Digitale J. Adolescent Girls Empowerment Programme: research and evaluation mid-term technical report, 2016.
16. Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. *Lancet (London, England)* 2012; 379(9823): 1320-9.
17. Balaeva T, Grjibovski AM, Sidorenkov O, et al. Seroprevalence and correlates of herpes simplex virus type 2 infection among young adults in Arkhangelsk, Northwest Russia: a population-based cross-sectional study. 2016; 16(1): 616.
18. Behanzin L, Diabate S, Minani I, et al. Decline in HIV Prevalence among Young Men in the General Population of Cotonou, Benin, 1998-2008. *PloS one* 2012; 7(8): e43818.
19. Benjamin RJ, Busch MP, Fang CT, et al. Human immunodeficiency virus-1 infection correlates strongly with herpes simplex virus-2 (genital herpes) seropositivity in South African and United States blood donations. *Transfusion* 2008; 48(2): 295-303.
20. Biraro S, Kamali A, White R, et al. Effect of HSV-2 on population-level trends in HIV incidence in Uganda between 1990 and 2007. *Tropical medicine & international health: TM & IH* 2013; 18(10): 1257-66.
21. Birdthistle IJ, Floyd S, Machingura A, Mudziwapasi N, Gregson S, Glynn JR. From affected to infected? Orphanhood and HIV risk among female adolescents in urban Zimbabwe. *Aids* 2008; 22(6): 759-66.
22. Biswas D, Borkakoty B, Mahanta J, et al. Seroprevalence and risk factors of herpes simplex virus type-2 infection among pregnant women in Northeast India. *BMC Infect Dis* 2011; 11: 325.
23. Bjerke SE, Holter E, Vangen S, Stray-Pedersen B. Sexually transmitted infections among Pakistani pregnant women and their husbands in Norway. *International journal of women's health* 2010; 2: 303-9.
24. Bochner AF, Madhivanan P, Niranjankumar B, et al. The Epidemiology of Herpes Simplex Virus Type-2 Infection among Pregnant Women in Rural Mysore Taluk, India. *Journal of sexually transmitted diseases* 2013; 2013: 750415.
25. Boni Cisse C, Zaba F, Meite S, et al. Seroprevalence of herpes simplex virus 2 infection among pregnant women in urban health training Yopougon-Attie (Cote D'ivoire). *Academic Journals* 2015; 6(3): 17-21.
26. Bradley J, Floyd S, Piwowar-Manning E, et al. Sexually transmitted bedfellows: exquisite association between HIV and herpes simplex virus type 2 in 21 communities in Southern Africa in the HIV prevention trials network 071 (PopART) Study. *Journal of Infectious Diseases* 2018; 218(3): 443-52.
27. Braunstein SL, Ingabire CM, Geubbels E, et al. High burden of prevalent and recently acquired HIV among female sex workers and female HIV voluntary testing center clients in Kigali, Rwanda. *PloS one* 2011a; 6(9): e24321.
28. Celentano DD, Mayer KH, Pequegnat W, et al. Prevalence of Sexually Transmitted Diseases and Risk Behaviors from the NIMH Collaborative HIV/STD Prevention Trial. *International journal of sexual health: official journal of the World Association for Sexual Health* 2010; 22(4): 272-84.
29. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2008.
30. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2010.
31. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2012.
32. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2014.

33. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2016.
34. Chawla R, Bhalla P, Bhalla K, Singh MM, Garg S. Community-based study on seroprevalence of herpes simplex virus type 2 infection in New Delhi. *Indian J Med Microbiol* 2008; 26(1): 34-9.
35. Chen L, Liu J, Shi L, et al. Seasonal influence on TORCH infection and analysis of multi-positive samples with indirect immunofluorescence assay. *J Clin Lab Anal* 2019; 33(4): e22828.
36. Cheslack-Postava K, Brown AS, Chudal R, et al. Maternal exposure to sexually transmitted infections and schizophrenia among offspring. *Schizophrenia research* 2015; 166(1-3): 255-60.
37. Conde-Glez C, Lazcano-Ponce E, Rojas R, et al. Seroprevalences of varicella-zoster virus, herpes simplex virus and cytomegalovirus in a cross-sectional study in Mexico. *Vaccine* 2013; 31(44): 5067-74.
38. Crucitti T, Jaspers V, Mulenga C, Khondowe S, Vandepitte J, Buve A. Non-sexual transmission of *Trichomonas vaginalis* in adolescent girls attending school in Ndola, Zambia. *PloS one* 2011; 6(1): e16310.
39. Dargham SR, Nasrallah GK, Al-Absi ES, et al. Herpes Simplex Virus Type 2 Seroprevalence Among Different National Populations of Middle East and North African Men. *Sex Transm Dis* 2018; 45(7): 482-7.
40. De Baetselier I, Menten J, Cuylaerts V, et al. Prevalence and incidence estimation of HSV-2 by two IgG ELISA methods among South African women at high risk of HIV. *PloS one* 2015; 10(3): e0120207.
41. Dhont N, van de Wijgert J, Luchters S, Muvunyi C, Vyankandondera J, Temmerman M. Sexual violence, HSV-2 and HIV are important predictors for infertility in Rwanda. *Human reproduction (Oxford, England)* 2010; 25(10): 2507-15.
42. Domercant JW, Jean Louis F, Hulland E, et al. Seroprevalence of Herpes Simplex Virus type-2 (HSV-2) among pregnant women who participated in a national HIV surveillance activity in Haiti. *BMC Infect Dis* 2017; 17(1): 577-.
43. Dorđević H. [Serological response to herpes simplex virus type 1 and 2 infection among women of reproductive age]. *Med Pregl* 2006; 59(11-12): 591-7.
44. Doyle AM, Ross DA, Maganja K, et al. Long-term biological and behavioural impact of an adolescent sexual health intervention in Tanzania: follow-up survey of the community-based MEMA kwa Vijana Trial. *PLoS medicine* 2010; 7(6): e1000287.
45. Duflo E, Dupas P, Kremer M. Education, HIV, and Early Fertility: Experimental Evidence from Kenya. *The American economic review* 2015; 105(9): 2757-97.
46. Fearon E, Wiggins RD, Pettifor AE, et al. Associations between friendship characteristics and HIV and HSV-2 status amongst young South African women in HPTN-068. *J Int AIDS Soc* 2017; 20(4).
47. Francis SC, Mthiyane TN, Baisley K, et al. Prevalence of sexually transmitted infections among young people in South Africa: A nested survey in a health and demographic surveillance site. *PLoS medicine* 2018; 15(2): e1002512.
48. Gabster A, Pascale JM, Cislaghi B, et al. High Prevalence of Sexually Transmitted Infections, and High-Risk Sexual Behaviors Among Indigenous Adolescents of the Comarca Ngäbe-Buglé, Panama. *Sex Transm Dis* 2019; 46(12): 780-7.
49. Glynn JR, Kayuni N, Gondwe L, Price AJ, Crampin AC. Earlier menarche is associated with a higher prevalence of Herpes simplex type-2 (HSV-2) in young women in rural Malawi. *eLife* 2014; 3: e01604.
50. Gonzalez TT, Sabino EC, Murphy EL, Chen S, Chamone DAF, McFarland W. Human immunodeficiency virus test-seeking motivation in blood donors, São Paulo, Brazil. *Vox Sang* 2006; 90(3): 170-6.
51. Gorfinkel IS, Aoki F, McNeil S, et al. Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial. *International Journal of STD and AIDS* 2013; 24(5): 345-9.
52. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. *The Lancet Infectious diseases* 2011; 11(7): 507-15.
53. Guwatudde D, Wabwire-Mangen F, Eller LA, et al. Relatively low HIV infection rates in rural Uganda, but with high potential for a rise: a cohort study in Kayunga District, Uganda. *PloS one* 2009; 4(1): e4145.
54. Hallfors DD, Cho H, Mbai, II, et al. Disclosure of HSV-2 serological test results in the context of an adolescent HIV prevention trial in Kenya. *Sex Transm Infect* 2015; 91(6): 395-400.
55. Han L, Husaiyin S, Wang X, Rouzi H, Niyazi M. Prevalence and risk factors of cervical cancer in the Nanjiang area of the Xinjiang Uyghur Autonomous Region of China: a matched case-control study. *European Journal of Gynaecological Oncology* 2021; 42(6): 1270-6.
56. Hazel A, Foxman B, Low BS. Herpes simplex virus type 2 among mobile pastoralists in northwestern Namibia. *Annals of human biology* 2015; 42(6): 543-51.
57. He N, Cao H, Yin Y, Gao M, Zhang T, Detels R. Herpes simplex virus-2 infection in male rural migrants in Shanghai, China. *Int J STD AIDS* 2009; 20(2): 112-4.
58. Herrera-Ortiz A, Conde-Glez CJ, Vergara-Ortega DN, García-Cisneros S, Olamendi-Portugal ML, Sánchez-Alemán MA. Avidity of antibodies against HSV-2 and risk to neonatal transmission among Mexican pregnant women. *Infect Dis Obstet Gynecol* 2013; 2013: 140142-.
59. Hochberg CH, Schneider JA, Dandona R, et al. Population and dyadic-based seroincidence of herpes simplex virus-2 and syphilis in southern India. *Sex Transm Infect* 2015; 91(5): 375-82.
60. Hikororo A, Kihunrwa A, Hoekstra P, et al. High prevalence of sexually transmitted infections in pregnant adolescent girls in Tanzania: a multi-community cross-sectional study. *Sex Transm Infect* 2015; 91(7): 473-8.
61. Hussan BM. Study the Prevalence of ACL, APL, CMV, HSV, Rubella and *Toxoplasma Gondii* in Aborted Women in Baghdad. *Medical Journal of Babylon* 2013; 10(2): 455-64.
62. Huai P, Li F, Li Z, et al. Seroprevalence and associated factors of HSV-2 infection among general population in Shandong Province, China. *BMC Infect Dis* 2019; 19(1): 382.
63. Jaspers V, Crucitti T, Menten J, et al. Prevalence and correlates of bacterial vaginosis in different sub-populations of women in sub-Saharan Africa: a cross-sectional study. *PloS one* 2014; 9(10): e109670.
64. Jozani ZB, Badie BM, Bayanolhagh S, et al. Knowledge, attitude, and practice towards HIV/AIDS conjoint with HIV, HBV, HCV and HSV2 serosurveys among girls from dysfunctional families in Tehran, Iran. *Journal of International Translational Medicine* 2019; 7(1): 33-8.
65. Kane CT, Diawara S, Ndiaye HD, et al. Concentrated and linked epidemics of both HSV-2 and HIV-1/HIV-2 infections in Senegal: public health impacts of the spread of HIV. *Int J STD AIDS* 2009; 20(11): 793-6.
66. Karaer A, Mert I, Cavkaytar S, Batioglu S. Serological investigation of the role of selected sexually transmitted infections in the aetiology of ectopic pregnancy. *The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception* 2013; 18(1): 68-74.

67. Kharsany ABM, McKinnon LR, Lewis L, et al. Population prevalence of sexually transmitted infections in a high HIV burden district in KwaZulu-Natal, South Africa: Implications for HIV epidemic control. *International Journal of Infectious Diseases* 2020; 98: 130-7.
68. Korr G, Thamm M, Czogiel I, Poethko-Mueller C, Bremer V, Jansen K. Decreasing seroprevalence of herpes simplex virus type 1 and type 2 in Germany leaves many people susceptible to genital infection: time to raise awareness and enhance control. *BMC Infect Dis* 2017; 17(1): 471.
69. Kucera P, Gerber S, Marques-Vidal P, Meylan PR. Seroepidemiology of herpes simplex virus type 1 and 2 in pregnant women in Switzerland: an obstetric clinic-based study. *European journal of obstetrics, gynecology, and reproductive biology* 2012; 160(1): 13-7.
70. Kuteesa MO, Weiss HA, Cook S, et al. Epidemiology of alcohol misuse and illicit drug use among young people aged 15-24 years in fishing communities in Uganda. *International Journal of Environmental Research and Public Health* 2020; 17 (7) (no pagination) (2401).
71. LeGoff J, Weiss HA, Gresenguet G, et al. Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. *Aids* 2007; 21(12): 1569-78.
72. Li JM, Chen YR, Li XT, Xu WC. Screening of Herpes simplex virus 2 infection among pregnant women in southern China. *J Dermatol* 2011; 38(2): 120-4.
73. Li Z, Yan R, Yan C, Liu P, Feng Z. Evaluation of an Automated Chemiluminescent Immunoassay in Typing Detection of IgG Antibodies Against Herpes Simplex Virus. *J Clin Lab Anal* 2016; 30(5): 577-80.
74. Lin H, He N, Su M, Feng J, Chen L, Gao M. Herpes simplex virus infections among rural residents in eastern China. *BMC Infect Dis* 2011; 11: 69.
75. Luseno WK, Hallfors DD, Cho H, et al. Use of HIV and HSV-2 biomarkers in sub-saharan adolescent prevention research: a comparison of two approaches. *The journal of primary prevention* 2014; 35(3): 181-91.
76. Madhivanan P, Chen YH, Krupp K, Arun A, Klausner JD, Reingold AL. Incidence of herpes simplex virus type 2 in young reproductive age women in Mysore, India. *Indian J Pathol Microbiol* 2011; 54(1): 96-9.
77. Marchi S, Trombetta CM, Gasparini R, Temperton N, Montomoli E. Epidemiology of herpes simplex virus type 1 and 2 in Italy: a seroprevalence study from 2000 to 2014. *Journal of preventive medicine and hygiene* 2017; 58(1): E27-e33.
78. Mawak JD, Dashe N, Atseye AB, Agabi YA, Zakeri H. Seroprevalence and co-infection of herpes simplex virus type 2 and human immunodeficiency virus in Nigeria. *Shiraz E Medical Journal* 2012; 13(1): 33-9.
79. Mehta SD, Nordgren RK, Agingu W, et al. Sexual Quality of Life and Association with HIV and Sexually Transmitted Infections Among a Cohort of Heterosexual Couples in Kenya. *Journal of Sexual Medicine* 2018; 15(10): 1446-55.
80. Memish ZA, Almasri M, Chentoufi AA, et al. Seroprevalence of Herpes Simplex Virus Type 1 and Type 2 and Coinfection with HIV and Syphilis: The First National Seroprevalence Survey in Saudi Arabia. *Sex Transm Dis* 2015; 42(9): 526-32.
81. Menezes LJ, Pokharel U, Sudenga SL, et al. Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial. *Sex Transm Infect* 2018; 94(1): 55-61.
82. Mensch BS, Grant MJ, Soler-Hampejsek E, Kelly CA, Chalasani S, Hewett PC. Does schooling protect sexual health? The association between three measures of education and STIs among adolescents in Malawi. *Population studies* 2020; 74(2): 241-61.
83. Mir AM, Wajid A, Reichenbach L, Khan M, Masood I. Herpes Simplex Virus-2 infection amongst urban male population in Pakistan. *J Pak Med Assoc* 2010; 60(11): 918-22.
84. Miskulin M, Miskulin I, Milas J, Antolovic-Pozgain A, Rudan S, Vuksic M. Prevalence and risk factors for herpes simplex virus type 2 infections in East Croatia. *Collegium antropologicum* 2011; 35(1): 9-14.
85. MOH Uganda, ORC Macro. Uganda HIV/AIDS sero-behavioural survey: 2004-2005: Calverton, Maryland, USA: Ministry of Health and ORC Macro., 2006.
86. Moreira-Soto A, Cabral R, Pedroso C, et al. Exhaustive TORCH Pathogen Diagnostics Corroborate Zika Virus Etiology of Congenital Malformations in Northeastern Brazil. *mSphere* 2018; 3(4).
87. Munawwar A, Gupta S, Sharma SK, Singh S. Seroprevalence of HSV-1 and 2 in HIV-infected males with and without GUD: Study from a tertiary care setting of India. *Journal of laboratory physicians* 2018; 10(3): 326-31.
88. Munro HL, Pradeep BS, Jayachandran AA, et al. Prevalence and determinants of HIV and sexually transmitted infections in a general population-based sample in Mysore district, Karnataka state, southern India. *Aids* 2008; 22: S117-S25.
89. Nag S, Sarkar S, Chattopadhyay D, Bhattacharya S, Biswas R, SenGupta M. Seroprevalence of Herpes Simplex Virus Infection in HIV Coinfected Individuals in Eastern India with Risk Factor Analysis. *Advances in virology* 2015; 2015: 537939.
90. Nakku-Joloba E, Kambugu F, Wasubire J, et al. Sero-prevalence of herpes simplex type 2 virus (HSV-2) and HIV infection in Kampala, Uganda. *African health sciences* 2014; 14(4): 782-9.
91. Nakubulwa S, Kaye DK, Bwanga F, Tumwesigye NM, Mirembe FM. Genital infections and risk of premature rupture of membranes in Mulago Hospital, Uganda: a case control study. *BMC research notes* 2015; 8: 573.
92. Nakubulwa S, Kaye DK, Bwanga F, Tumwesigye NM, Nakku-Joloba E, Mirembe FM. Incidence and risk factors for herpes simplex virus type 2 seroconversion among pregnant women in Uganda: A prospective study. *Journal of infection in developing countries* 2016; 10(10): 1108-15.
93. NASCOP (National AIDS/STI Control Program). 2007 Kenya AIDS Indicator Survey: Final Report. Nairobi, Kenya, September 2009.
94. Nasrallah G, Dargham S, Harfouche M, Abu-Raddad L. Seroprevalence of Herpes simplex virus types 1 and 2 in Indian and Filipino migrant populations in Qatar: a cross-sectional survey. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit* 2020; 26(5): 609-15.
95. Norris AH, Kitali AJ, Worby E. Alcohol and transactional sex: how risky is the mix? *Social science & medicine* (1982) 2009; 69(8): 1167-76.
96. Nyiro JU, Sanders EJ, Ngetsa C, et al. Seroprevalence, predictors and estimated incidence of maternal and neonatal Herpes Simplex Virus type 2 infection in semi-urban women in Kilifi, Kenya. *BMC Infect Dis* 2011; 11: 155.
97. Oliver VO, Otieno G, Gvetadze R, et al. High prevalence of sexually transmitted infections among women screened for a contraceptive intravaginal ring study, Kisumu, Kenya, 2014. *International Journal of STD and AIDS* 2018; 29(14): 1390-9.
98. Otieno FO, Ndivo R, Oswago S, et al. Correlates of prevalent sexually transmitted infections among participants screened for an HIV incidence cohort study in Kisumu, Kenya. *Int J STD AIDS* 2015; 26(4): 225-37.
99. Papadogeorgakis H, Caroni C, Katsambas A, et al. Herpes simplex virus seroprevalence among children, adolescents and adults in Greece. *Int J STD AIDS* 2008; 19(4): 272-8.
100. Pascoe SJ, Langhaug LF, Mavhu W, et al. Poverty, food insufficiency and HIV infection and sexual behaviour among young rural Zimbabwean women. *PloS one* 2015; 10(1): e0115290.
101. Patzi-Churqui M, Terrazas-Aranda K, Liljeqvist JA, Lindh M, Eriksson K. Prevalence of viral sexually transmitted infections and HPV high-risk genotypes in women in rural communities in the Department of La Paz, Bolivia. *BMC Infect Dis* 2020; 20(1): 204.



102. Paz-Bailey G, Morales-Miranda S, Jacobson JO, et al. High rates of STD and sexual risk behaviors among Garifunas in Honduras. *J Acquir Immune Defic Syndr* 2009; 51 Suppl 1: S26-34.
103. Price J, Pettifor A, Selin A, et al. The association between perceived household educational support and HIV risk in young women in a rural South African community (HPTN 068): A cross sectional study. *PLoS one* 2019; 14(1): e0210632.
104. Rahman S, Wathington D, Waterboer T, et al. Seroprevalence of Chlamydia trachomatis, herpes simplex 2, Epstein-Barr virus, hepatitis C and associated factors among a cohort of men ages 18–70 years from three countries. *PLoS one* 2021; 16(6): e0253005.
105. Rajaram SP, Bradley JE, Ramesh BM, et al. P1-S1.14 Is HIV prevalence declining in Southern India? Evidence from two rounds of general population surveys in Bagalkot District, Karnataka. *Sexually Transmitted Infections* 2011; 87(Suppl 1): A105-A.
106. Rathore S, Jamwal A, Gupta V. Herpes simplex virus type 2: Seroprevalence in antenatal women. *Indian journal of sexually transmitted diseases* 2010; 31(1): 11.
107. Remis RS, Liu J, Loutfy M, et al. The epidemiology of sexually transmitted co-infections in HIV-positive and HIV-negative African-Caribbean women in Toronto. *BMC Infect Dis* 2013; 13: 550.
108. Rostamzadeh Khameneh Z, Sepehrvand N, Mohammadian M. Herpes Simplex Virus Type 2 Seroprevalence in Pregnant Women in Urmia, Northwest of Iran, during 2014-2015. *Iran Biomed J* 2020; 24(2): 136-9.
109. Rotermann M, Langlois KA, Severini A, Totten S. Prevalence of Chlamydia trachomatis and herpes simplex virus type 2: Results from the 2009 to 2011 Canadian Health Measures Survey. *Health reports* 2013; 24(4): 10-5.
110. Sasadeusz JJ, Silvers JE, Kent HE, Devenish W, Hocking J, Garland SM. Prevalence of HSV-2 antibody in a Melbourne antenatal population attending a tertiary obstetric hospital. *The Australian & New Zealand journal of obstetrics & gynaecology* 2008; 48(3): 266-72.
111. Schneider JA, Lakshmi V, Dandona R, Kumar GA, Sudha T, Dandona L. Population-based seroprevalence of HSV-2 and syphilis in Andhra Pradesh state of India. *BMC Infect Dis* 2010b; 10: 59.
112. Sgaier SK, Mony P, Jayakumar S, et al. Prevalence and correlates of Herpes Simplex Virus-2 and syphilis infections in the general population in India. *Sex Transm Infect* 2011; 87(2): 94-100.
113. Shahraki AD, Moghim S, Akbari P. A survey on herpes simplex type 2 antibody among pregnant women in Isfahan, Iran. *Journal of Research in Medical Sciences* 2010; 15(4).
114. Shen JH, Huang KY, Chao-Yu C, Chen CJ, Lin TY, Huang YC. Seroprevalence of Herpes Simplex Virus Type 1 and 2 in Taiwan and Risk Factor Analysis. *PLoS one* 2015; 10(8): e0134178.
115. Shin HS, Park JJ, Chu C, et al. Herpes simplex virus type 2 seroprevalence in Korea: rapid increase of HSV-2 seroprevalence in the 30s in the southern part. *Journal of Korean medical science* 2007; 22(6): 957-62.
116. Sivapalasingam S, McClelland RS, Ravel J, et al. An effective intervention to reduce intravaginal practices among HIV-1 uninfected Kenyan women. *AIDS Research and Human Retroviruses* 2014; 30(11): 1046-54.
117. Suligoi B, Quaglio G, Regine V, et al. Seroprevalence of HIV, HSV-2, and Treponema pallidum in the Kosovarian population. *Scandinavian journal of infectious diseases* 2009; 41(8): 608-13.
118. Tobian AA, Charvat B, Sempijija V, et al. Factors associated with the prevalence and incidence of herpes simplex virus type 2 infection among men in Rakai, Uganda. *The Journal of infectious diseases* 2009; 199(7): 945-9.
119. Tobian AA, Kigozi G, Redd AD, et al. Male circumcision and herpes simplex virus type 2 infection in female partners: a randomized trial in Rakai, Uganda. *The Journal of infectious diseases* 2012; 205(3): 486-90.
120. Todd CS, Nasir A, Mansoor GF, et al. Cross-sectional assessment of prevalence and correlates of blood-borne and sexually transmitted infections among Afghan National Army recruits. *BMC Infect Dis* 2012; 12: 196.
121. Topbas M, Can E, Kaklikkaya N, Yavuzylmaz A, Ozkan G, Can G. Herpes simplex virus type-2 seroprevalence among adults aged 20-49 in Trabzon. *Nobel Medicus* 2012; 8(2): 85-90.
122. Valley A, Ryan CE, Allen J, et al. High prevalence and incidence of HIV, sexually transmissible infections and penile foreskin cutting among sexual health clinic attendees in Papua New Guinea. *Sex Health* 2014; 11(1): 58-66.
123. Valley AJ, MacLaren D, David M, et al. Dorsal longitudinal foreskin cut is associated with reduced risk of HIV, syphilis and genital herpes in men: a cross-sectional study in Papua New Guinea. *J Int AIDS Soc* 2017; 20(1): 21358.
124. Valley LM, Toliman P, Ryan C, et al. Prevalence and risk factors of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and other sexually transmissible infections among women attending antenatal clinics in three provinces in Papua New Guinea: a cross-sectional survey. *Sex Health* 2016; 13(5): 420-7.
125. Vilibić-Čavlek T, Kolaric B, Bogdanić M, Tabain I, Beader N. Herpes Group Viruses: a Seroprevalence Study in Hemodialysis Patients. *Acta Clin Croat* 2017; 56(2): 255-61.
126. Vilibić-Čavlek T, Ljubin-Sternak S, Ban M, Kolaric B, Sviben M, Mlinaric-Galinovic G. Seroprevalence of TORCH infections in women of childbearing age in Croatia. *The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet* 2011; 24(2): 280-3.
127. Wang LC, Yan F, Ruan JX, Xiao Y, Yu Y. TORCH screening used appropriately in China?—three years results from a teaching hospital in northwest China. *BMC pregnancy and childbirth* 2019; 19(1): 484.
128. Warnecke JM, Pollmann M, Borchardt-Loholter V, et al. Seroprevalences of antibodies against TORCH infectious pathogens in women of childbearing age residing in Brazil, Mexico, Germany, Poland, Turkey and China. *Epidemiology and Infection* 2020.
129. Winston SE, Chirchir AK, Muthoni LN, et al. Prevalence of sexually transmitted infections including HIV in street-connected adolescents in western Kenya. *Sex Transm Infect* 2015; 91(5): 353-9.
130. Woestenberg PJ, Tjhi JH, de Melker HE, et al. Herpes simplex virus type 1 and type 2 in the Netherlands: seroprevalence, risk factors and changes during a 12-year period. *BMC Infect Dis* 2016; 16: 364.
131. Yegorov S, Galiwango RM, Good SV, et al. Schistosoma mansoni infection and socio-behavioural predictors of HIV risk: a cross-sectional study in women from Uganda. *BMC Infect Dis* 2018; 18(1): 586.
132. Zhang JF, Zhang WY. [Relationship of cytomegalovirus, Chlamydia pneumoniae and herpes simplex virus type 2 infections with preeclampsia]. *Zhonghua Yi Xue Za Zhi* 2012; 92(20): 1413-5.
133. Zhang T, Yang Y, Yu F, et al. Kaposi's sarcoma associated herpesvirus infection among female sex workers and general population women in Shanghai, China: a cross-sectional study. *BMC Infect Dis* 2014; 14: 58.
134. Zulaika G, van Eijk AM, Mason L, et al. Factors associated with the prevalence of HIV, HSV-2, pregnancy, and reported sexual activity among adolescent girls in rural western Kenya: A cross-sectional analysis of baseline data in a cluster randomized controlled trial. *PLoS Medicine* 2021; 18(9): e1003756.

Abbreviations: HSV = Herpes simplex virus.

## Box S5. List of articles on the general population from which an HSV-1 prevalence measure was extracted and included in the meta-analyses.

1. Abbas AH, KrikorMelconian A, Ad'hiah AH. No etiological role of Herpes Simplex Virus and Toxoplasma Gondii infections in systemic lupus erythematosus of Iraqi Female Patients. *Biochemical and Cellular Archives* 2019; 19(1): 919-21.
2. Al-Hakami AM, Paul E, Al-Abed F, et al. Prevalence of toxoplasmosis, rubella, cytomegalovirus, and herpes (TORCH) infections among women attending the antenatal care clinic, maternity hospital in Abha, Southwestern Saudi Arabia. *Saudi Med J* 2020; 41(7): 757-62.
3. Al-Hatemi LA, Kadhim RA, Al-Rubaye AF. Relationship of rheumatoid arthritis with microbial pathogens (TORCH Test), case-control study in Iraq. *Journal of Cardiovascular Disease Research* 2020; 11(4): 230-4.
4. Al-Shuwaikh AMA, Hanna DB, Ali ZQ. Seroprevalence of herpes simplex Virus type-1 IgG Antibody in Healthy Blood Donor from Baghdad, Iraq. *Journal of Pure and Applied Microbiology* 2019; 13(2): 1017-23.
5. Althaqafi RMM, Elrewiny M, Abdel-Moneim AS. Maternal and neonatal infections of herpes simplex virus-1 and cytomegalovirus in Saudi Arabia. *J Infect Public Health* 2020; 13(2): 313-4.
6. Arama V, Cercel AS, Vladareanu R, et al. Type-specific herpes simplex virus-1 and herpes simplex virus-2 seroprevalence in Romania: comparison of prevalence and risk factors in women and men. *International journal of infectious diseases: IJID : official publication of the International Society for Infectious Diseases* 2010; 14 Suppl 3: e25-31.
7. Arama V, Vladareanu R, Mihailescu R, et al. Seroprevalence and risk factors associated with herpes simplex virus infection among pregnant women. *Journal of perinatal medicine* 2008; 36(3): 206-12.
8. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2004; 10(6): 530-6.
9. Ben Fredj N, Nefzi F, Aouni M, et al. Evaluation of the implication of KIR2DL2 receptor in multiple sclerosis and herpesvirus susceptibility. *Journal of Neuroimmunology* 2014; 271(1-2): 30-5.
10. Ben Fredj N, Nefzi F, Aouni M, et al. Identification of human herpesviruses 1 to 8 in Tunisian multiple sclerosis patients and healthy blood donors. *Journal of NeuroVirology* 2012; 18(1): 12-9.
11. Benharrosh J, Dauphin H, Porcheret H, Meritet JF, Boulanger MC, Maisonneuve L. [Comparison of two ELISA tests to study the seroprevalence of herpes simplex 1 et 2 infection in a maternity near Paris]. *Annales de biologie clinique* 2008; 66(6): 665-70.
12. Blomstrom A, Karlsson H, Wicks S, Yang S, Yolken RH, Dalman C. Maternal antibodies to infectious agents and risk for non-affective psychoses in the offspring--a matched case-control study. *Schizophrenia research* 2012; 140(1-3): 25-30.
13. Bogaerts J, Ahmed J, Akhter N, et al. Sexually transmitted infections among married women in Dhaka, Bangladesh: unexpected high prevalence of herpes simplex type 2 infection. *Sexually transmitted infections* 2001; 77(2): 114-9.
14. Brazzale AG, Russell DB, Cunningham AL, Taylor J, McBride WJ. Seroprevalence of herpes simplex virus type 1 and type 2 among the Indigenous population of Cape York, Far North Queensland, Australia. *Sex Health* 2010; 7(4): 453-9.
15. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2008.
16. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2010.
17. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2012.
18. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2014.
19. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2016.
20. Chen CY, Shen JH, Huang YC. Seroepidemiology of Epstein-Barr virus and herpes simplex virus-1 in Taiwan. *International Journal of Antimicrobial Agents* 2013; 42(SUPPL. 2): S135.
21. Chen L, Liu J, Shi L, et al. Seasonal influence on TORCH infection and analysis of multi-positive samples with indirect immunofluorescence assay. *J Clin Lab Anal* 2019; 33(4): e22828.
22. Cliff JM, King EC, Lee JS, et al. Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). *Front Immunol* 2019; 10: 796.
23. Conde-Glez C, Lazcano-Ponce E, Rojas R, et al. Seroprevalences of varicella-zoster virus, herpes simplex virus and cytomegalovirus in a cross-sectional study in Mexico. *Vaccine* 2013; 31(44): 5067-74.
24. Cowan FM, French RS, Mayaud P, et al. Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka. *Sexually transmitted infections* 2003; 79(4): 286-90.
25. Dordevic H. [Serological response to herpes simplex virus type 1 and 2 infection among women of reproductive age]. *Med Pregl* 2006; 59(11-12): 591-7.
26. Dworzanski J, Drop B, Kliszczewska E, Polz-Dacewicz M, StrycharzDudziak M. Prevalence of Epstein-Barr virus, human papillomavirus, cytomegalovirus and herpes simplex virus type 1 in patients with diabetes mellitus type 2 in south-eastern Poland. *PloS one* 2019; 14(9): e0222607.
27. Ghebrekidan H, Ruden U, Cox S, Wahren B, Grandien M. Prevalence of herpes simplex virus types 1 and 2, cytomegalovirus, and varicella-zoster virus infections in Eritrea. *Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology* 1999; 12(1): 53-64.
28. Gorfinkel IS, Aoki F, McNeil S, et al. Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial. *Int J STD AIDS* 2013; 24(5): 345-9.

29. Halawi M, Al-Hazmi A, Aljuaid A, et al. Seroprevalence of *Toxoplasma gondii*, Rubella, Group A Streptococcus, CMV and HSV-1 in COVID-19 Patients with Vitamin D Deficiency. *Pak J Biol Sci* 2021; 24(11): 1169-74.
30. Hamdani N, Daban-Huad C, Godin O, et al. Effects of Cumulative Herpesviridae and *Toxoplasma gondii* Infections on Cognitive Function in Healthy, Bipolar, and Schizophrenia Subjects. *The Journal of clinical psychiatry* 2017; 78(1): e18-e27.
31. Hemmingsson ES, Hjelmare E, Weidung B, et al. Antiviral treatment associated with reduced risk of clinical Alzheimer's disease-A nested case-control study. *Alzheimer's and Dementia: Translational Research and Clinical Interventions* 2021; 7(1): e12187.
32. Hogrefe W, Su X, Song J, Ashley R, Kong L. Detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in African sera by using recombinant gG2, Western blotting, and gG2 inhibition. *Journal of clinical microbiology* 2002; 40(10): 3635-40.
33. Igde AF, Igde M, Yazici Z, et al. Distribution of HSV-1 IgG antibodies by two methods comparing in Turkish atopic children. *The new microbiologica* 2007; 30(2): 109-12.
34. Igde M, Igde FA, Yazici Z. Herpes simplex type I infection and atopy association in Turkish children with asthma and allergic rhinitis. *Iranian Journal of Allergy, Asthma and Immunology* 2009; 8(3): 149-54.
35. Ihsan AK, Rajaa A-J. Evaluation of immunoglobulines versus natural salivary defense in controlling recurrent herpes simplex lesions. *Journal of baghdad college of dentistry* 9-63 : (4)21 ;2009 *مجلة كلية طب الاسنان بغداد*.
36. Irschick EU, Philipp S, Shahram F, et al. Investigation of bacterial and viral agents and immune status in Behcet's disease patients from Iran. *Int J Rheum Dis* 2011; 14(3): 298-310.
37. Jafarzadeh A, Nemati M, Tahmasbi M, Ahmadi P, Rezayati MT, Sayadi AR. The association between infection burden in Iranian patients with acute myocardial infarction and unstable angina. *Acta Med Indones* 2011; 43(2): 105-11.
38. Jansen MA, van den Heuvel D, Bouthoorn SH, et al. Determinants of Ethnic Differences in Cytomegalovirus, Epstein-Barr Virus, and Herpes Simplex Virus Type 1 Seroprevalence in Childhood. *The Journal of pediatrics* 2016; 170: 126-34.e1-6.
39. Jary A, Burrel S, Boutolleau D, et al. Prevalence of cervical HPV infection, sexually transmitted infections and associated antimicrobial resistance in women attending cervical cancer screening in Mali. *International Journal of Infectious Diseases* 2021; 108: 610-6.
40. Juhl D, Mosel C, Nawroth F, et al. Detection of herpes simplex virus DNA in plasma of patients with primary but not with recurrent infection: implications for transfusion medicine? *Transfusion medicine (Oxford, England)* 2010; 20(1): 38-47.
41. Karachaliou M, Waterboer T, Casabonne D, et al. The natural history of human polyomaviruses and herpesviruses in early life - The rhea birth cohort in Greece. *American Journal of Epidemiology* 2016; 183(7): 671-9.
42. Kasubi MJ, Nilsen A, Marsden HS, Bergstrom T, Langeland N, Haarr L. Prevalence of antibodies against herpes simplex virus types 1 and 2 in children and young people in an urban region in Tanzania. *Journal of clinical microbiology* 2006; 44(8): 2801-7.
43. Kaur R, Gupta N, Baveja UK. Seroprevalence of HSV1 and HSV2 infections in family planning clinic attenders. *The Journal of communicable diseases* 2005; 37(4): 307-9.
44. Korr G, Thamm M, Czogiel I, Poethko-Mueller C, Bremer V, Jansen K. Decreasing seroprevalence of herpes simplex virus type 1 and type 2 in Germany leaves many people susceptible to genital infection: time to raise awareness and enhance control. *BMC Infect Dis* 2017; 17(1): 471.
45. Kramer MA, Uitenbroek DG, Ujcic-Voortman JK, et al. Ethnic differences in HSV1 and HSV2 seroprevalence in Amsterdam, the Netherlands. *Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin* 2008; 13(24).
46. Kucera P, Gerber S, Marques-Vidal P, Meylan PR. Seroepidemiology of herpes simplex virus type 1 and 2 in pregnant women in Switzerland: an obstetric clinic-based study. *European journal of obstetrics, gynecology, and reproductive biology* 2012; 160(1): 13-7.
47. LeGoff J, Gresenguet G, Gody C, et al. Performance of the BioPlex 2200 multiplexing immunoassay platform for the detection of herpes simplex virus type 2 specific antibodies in African settings. *Clinical and Vaccine Immunology* 2011; 18(7): 1191-3.
48. LeGoff J, Sausseureau E, Boulanger MC, et al. Unexpected high prevalence of herpes simplex virus (HSV) type 2 seropositivity and HSV genital shedding in pregnant women living in an East Paris suburban area. *Int J STD AIDS* 2007; 18(9): 593-5.
49. Leutscher P, Jensen JS, Hoffmann S, et al. Sexually transmitted infections in rural Madagascar at an early stage of the HIV epidemic: a 6-month community-based follow-up study. *Sex Transm Dis* 2005; 32(3): 150-5.
50. Li C, Li Y, Yang Y, et al. The Detection and Characterization of Herpes Simplex Virus Type 1 in Confirmed Measles Cases. *Sci Rep* 2019; 9(1): 12785.
51. Lin H, He N, Su M, Feng J, Chen L, Gao M. Herpes simplex virus infections among rural residents in eastern China. *BMC Infect Dis* 2011; 11: 69.
52. Marrazzo J, Rabe L, Kelly C, et al. Herpes simplex virus (HSV) infection in the VOICE (MTN 003) study: Pre-exposure prophylaxis (PrEP) for HIV with daily use of oral tenofovir, oral tenofovir-emtricitabine, or vaginal tenofovir gel. *Sexually Transmitted Infections Conference: STI and AIDS World Congress 2013*; 89(no pagination).
53. Matrajt L, Gantt S, Mayer BT, et al. Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children. *Sci Rep* 2017; 7(1): 13105.
54. Memish ZA, Almasri M, Chentoufi AA, et al. Seroprevalence of Herpes Simplex Virus Type 1 and Type 2 and Coinfection with HIV and Syphilis: The First National Seroprevalence Survey in Saudi Arabia. *Sex Transm Dis* 2015; 42(9): 526-32. doi: 10.1097/OLQ.0000000000000336.
55. Mihret W, Rinke De Wit TF, Petros B, et al. Herpes simplex virus type 2 seropositivity among urban adults in Africa: Results from two cross-sectional surveys in Addis Ababa, Ethiopia. *Sexually Transmitted Diseases* 2002; 29(3): 175-81.
56. Nakku-Joloba E, Kambugu F, Wasubire J, et al. Sero-prevalence of herpes simplex type 2 virus (HSV-2) and HIV infection in Kampala, Uganda. *African health sciences* 2014; 14(4): 782-9.
57. Nasrallah GK, Dargham SR, Mohammed LI, Abu-Raddad LJ. Estimating seroprevalence of herpes simplex virus type 1 among different Middle East and North African male populations residing in Qatar. *J Med Virol* 2017; 17(10): 24916.
58. Neal JD, Tobian AA, Laeyendecker O, et al. Performance of the Euroline Western blot assay in the detection of herpes simplex virus type 2 antibody in Uganda, China and the USA. *Int J STD AIDS* 2011; 22(6): 342-4.
59. Nissen J, Trabjerg B, Pedersen MG, et al. Herpes Simplex Virus Type 1 infection is associated with suicidal behavior and first registered psychiatric diagnosis in a healthy population. *Psychoneuroendocrinology* 2019; 108: 150-4.

60. Papadogeorgakis H, Caroni C, Katsambas A, et al. Herpes simplex virus seroprevalence among children, adolescents and adults in Greece. *Int J STD AIDS* 2008; 19(4): 272-8.
61. Patnaik P, Herrero R, Morrow RA, et al. Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. *Sex Transm Dis* 2007; 34(12): 1019-24.
62. Perti T, Nyati M, Gray G, et al. Frequent genital HSV-2 shedding among women during labor in Soweto, South Africa. *Infectious diseases in obstetrics and gynecology* 2014; 2014: 258291.
63. Pourmand D, Janbakhsh A. Seroepidemiology of herpes simplex virus type one in pregnant women referring to health care centers of Kermanshah (2004). *Behboob* 2009; 14(1): 96-100.
64. Puhakka L, Sarvikivi E, Lappalainen M, Surcel HM, Saxen H. Decrease in seroprevalence for herpesviruses among pregnant women in Finland: cross-sectional study of three time points 1992, 2002 and 2012. *Infectious diseases (London, England)* 2016; 48(5): 406-10.
65. Remis RS, Liu J, Loutfy M, et al. The epidemiology of sexually transmitted co-infections in HIV-positive and HIV-negative African-Caribbean women in Toronto. *BMC Infect Dis* 2013; 13: 550.
66. Rezaei-Chaparpordi S, Assmar M, Amirmozafari N, et al. Seroepidemiology of herpes simplex virus type 1 and 2 in northern Iran. *Iran J Public Health* 2012; 41(8): 75-9. Epub 2012 Aug 31.
67. Salloom Df, Saleh DS, Al-Khafaji JT. Detection of Anti-Chlamydia pneumonia IgG and Anti-HSV-1 IgG antibodies in sample of Iraqi Behcet's disease patients *Journal of Biotechnology Research Center* 2014; 8(2): 34-6.
68. Shen JH, Huang KY, Chao-Yu C, Chen CJ, Lin TY, Huang YC. Seroprevalence of Herpes Simplex Virus Type 1 and 2 in Taiwan and Risk Factor Analysis, 2007. *PloS one* 2015; 10(8): e0134178.
69. Shivaswamy K, Thappa DM, Jaisankar T, Sujatha S. High seroprevalence of HSV-1 and HSV-2 in STD clinic attendees and non-high-risk controls: a case control study at a referral hospital in south India. *Indian Journal of Dermatology, Venereology & Leprology* 2005; 71(1).
70. Snijders GJLJ, van Mierlo HC, Boks MP, et al. The association between antibodies to neurotropic pathogens and bipolar disorder: A study in the Dutch Bipolar (DB) Cohort and meta-analysis. *Translational Psychiatry* 2019; 9(1): 311.
71. Tedla Y, Shibre T, Ali O, et al. Serum antibodies to toxoplasma gondii and herpesviridae family viruses in individuals with schizophrenia and bipolar disorder: A Case - Control study. *Ethiopian Medical Journal* 2011; 49(3): 211-20.
72. Thomas P, Bhatia T, Gauba D, et al. Exposure to herpes simplex virus, type 1 and reduced cognitive function. *Journal of Psychiatric Research* 2013; 47(11): 1680-5.
73. Vilibic-Cavlek T, Kolaric B, Bogdanic M, Tabain I, Beader N. Herpes Group Viruses: a Seroprevalence Study in Hemodialysis Patients. *Acta clinica Croatica* 2017; 56(2): 255-61.
74. Vilibic-Cavlek T, Kolaric B, Ljubin-Sternak S, Mlinaric-Galinovic G. Herpes simplex virus infection in the Croatian population. *Scandinavian journal of infectious diseases* 2011; 43(11-12): 918-22.
75. Vilibic-Cavlek T, Ljubin-Sternak S, Ban M, Kolaric B, Sviben M, Mlinaric-Galinovic G. Seroprevalence of TORCH infections in women of childbearing age in Croatia. *The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet* 2011; 24(2): 280-3.
76. Wang H, Yolken RH, Hoekstra PJ, Burger H, Klein HC. Antibodies to infectious agents and the positive symptom dimension of subclinical psychosis: The TRAILS study. *Schizophrenia Research* 2011; 129(1): 47-51.
77. Wang L-C, Ruan J-X, Xiao Y, Yan F, Yu Y. TORCH screening used appropriately in China? - Three years results from a teaching hospital in northwest China. *BMC Pregnancy and Childbirth* 2019; 19(1): 484.
78. Warnecke JM, Pollmann M, Borchardt-Loholter V, et al. Seroprevalences of antibodies against ToRCH infectious pathogens in women of childbearing age residing in Brazil, Mexico, Germany, Poland, Turkey, and China. *Epidemiology and Infection* 2020; 148: e271.
79. Woestenbergh PJ, Tjhi JH, de Melker HE, et al. Herpes simplex virus type 1 and type 2 in the Netherlands: seroprevalence, risk factors and changes during a 12-year period. *BMC Infect Dis* 2016; 16: 364.
80. Zangana LMM. Seroprevalence of Herpes Simplex Virus type-1 antibodies (IgM, IgG) in smokers in Kirkuk city-Iraq *Tikrit Journal of Pure Science* 2016; 21(1): 36-40.
81. Zhang Y, Traskman-Bendz L, Janelidze S, et al. Toxoplasma gondii immunoglobulin G antibodies and nonfatal suicidal self-directed violence. *The Journal of clinical psychiatry* 2012; 73(8): 1069-76.
82. Ziyaeyan M, Japoni A, Roostae MH, Salehi S, Soleimanjahi H. A serological survey of Herpes Simplex Virus type 1 and 2 immunity in pregnant women at labor stage in Tehran, Iran. *Pak J Biol Sci* 2007; 10(1): 148-51.

Abbreviations: HSV = Herpes simplex virus.

**Table S3.** HSV-2 prevalence measures among general populations included in the WHO HSV estimations, by region, sex, and age group.

WHO Region	Sex	Number of data points that contributed to the estimation by age group (in years)							Countries with data
		15-19	20-24	25-29	30-34	35-39	40-44	45-49	
African	Females	45	33	27	19	9	8	4	Benin, Côte d'Ivoire, Ethiopia, Kenya, Malawi, Namibia, Nigeria, Rwanda, Senegal, South Africa, Tanzania, Uganda, Zambia, Zimbabwe
	Males	17	22	10	11	5	10	4	Benin, Kenya, Malawi, Namibia, Nigeria, Rwanda, South Africa, Tanzania, Uganda, Zambia
Americas	Females	7	8	11	11	7	8	7	Bolivia, Brazil, Canada, Haiti, Honduras, Mexico, Panama, USA
	Males	6	6	6	6	6	11	6	Brazil, Canada, Honduras, Mexico, Panama, USA
Eastern Mediterranean	Females	1	1	4	6	1	-	-	Iran, Iraq, Pakistan, Saudi Arabia, Sudan
	Males	4	2	10	5	8	5	5	Afghanistan, Egypt, Iraq, Jordan, Lebanon, Pakistan, Palestine, Qatar, Saudi Arabia, Syria
European	Females	6	11	15	16	10	7	6	Croatia, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Romania, Russia, Serbia, Sweden, Switzerland, Turkey
	Males	3	9	7	10	8	6	5	Croatia, Germany, Greece, Italy, Netherlands, Norway, Romania, Russia, Serbia, Sweden, Turkey
South-East Asia	Females	4	6	8	4	4	3	1	India
	Males	1	3	4	6	3	4	2	India
Western Pacific	Females	2	7	12	12	6	5	7	Australia, China, Korea, Papua New Guinea, Vietnam
	Males	2	5	6	8	4	5	4	Australia, China, Korea, Papua New Guinea, Philippines

Abbreviations: HSV= Herpes simplex virus, USA = United States of America, WHO = World Health Organization.  
Regions are per World Health Organization definitions.

**Table S4.** HSV-1 prevalence measures among general populations included in the WHO HSV estimations, by region, sex, and age group.

WHO Region	Sex	Number of data points that contributed to the estimation by age group (in years)										Countries with data
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	
<b>African</b>	Females, males, and mixed sexes	3	2	3	4	-	6	7	2	2	-	Central African Republic, Mali, South Africa, Uganda, Zimbabwe
<b>Americas</b>	Females	-	2 <sup>a</sup>	10 <sup>a</sup>	6	6	8	9	6	5	5	Brazil, Canada, Mexico, USA
	Males				6	5	6	6	6	5	5	Mexico, USA
<b>Eastern Mediterranean</b>	Females, males, and mixed sexes	-	-	-	3	4	8	7	17	7	5	Egypt, Iran, Iraq, Jordan, Lebanon, Morocco, Pakistan, Palestine, Qatar, Sudan, Syria, Tunisia, Yemen
<b>European</b>	Females	7 <sup>a</sup>	6 <sup>a</sup>	5 <sup>a</sup>	4	6	10	10	5	5	2	Croatia, Finland, France, Germany, Greece, Netherland, Poland, Romania, Serbia, Sweden, Switzerland, Turkey
	Males				2	3	4	3	3	3	2	Germany, Greece, Netherland, Romania, Sweden
<b>South-East Asia</b>	Females, males, and mixed sexes	-	1	-	4	2	3	8	2	4	1	India, Indonesia
<b>Western Pacific</b>	Females, males, and mixed sexes	2	12	5	2	5	4	15	3	6	5	Australia, China, Philippines

Abbreviations: HSV = Herpes simplex virus, USA = United States of America, WHO = World Health Organization.

<sup>a</sup>These measures included females, males, and mixed sexes for given age bands.

Regions are per World Health Organization definitions.


**Table S5.** Comparison of HSV estimates over the WHO HSV estimation rounds [15, 17-19].

2012 global estimates	2016 global estimates	2020 global estimates
<ul style="list-style-type: none"> <li>• 37 articles were used as modelling input for HSV-1</li> <li>• 111 articles were used as modelling input for HSV-2</li> </ul>	<ul style="list-style-type: none"> <li>• 44 articles were used as modelling input for HSV-1</li> <li>• 88 articles were used as modelling input for HSV-2</li> </ul>	<ul style="list-style-type: none"> <li>• 82 articles were used as modelling input for HSV-1</li> <li>• 134 articles were used as modelling input for HSV-2</li> </ul>
<b>HSV-1 incidence at any site (oral and genital):</b> <ul style="list-style-type: none"> <li>• 118.0 million new HSV-1 infections among individuals aged 0-49 years</li> <li>• HSV-1 incidence rate of 2.0%</li> </ul>	<b>HSV-1 incidence at any site (oral and genital):</b> <ul style="list-style-type: none"> <li>• 120.4 million new HSV-1 infections among individuals aged 0-49 years</li> <li>• HSV-1 incidence rate of 2.1%</li> </ul>	<b>HSV-1 incidence at any site (oral and genital):</b> <ul style="list-style-type: none"> <li>• 122.2 million new HSV-1 infections among individuals aged 0-49 years</li> <li>• HSV-1 incidence rate of 2.1%</li> </ul>
<b>HSV-1 prevalence at any site (oral and genital):</b> <ul style="list-style-type: none"> <li>• 3,709.0 million HSV-1 prevalent infections among individuals aged 0-49 years</li> <li>• HSV-1 prevalence of 67.0%</li> </ul>	<b>HSV-1 prevalence at any site (oral and genital):</b> <ul style="list-style-type: none"> <li>• 3,752.0 million HSV-1 prevalent infections among individuals aged 0-49 years</li> <li>• HSV-1 prevalence of 66.6%</li> </ul>	<b>HSV-1 prevalence at any site (oral and genital):</b> <ul style="list-style-type: none"> <li>• 3,779.1 million HSV-1 prevalent infections among individuals aged 0-49 years</li> <li>• HSV-1 prevalence of 64.2%</li> </ul>
<b>Oral HSV-1 prevalence:</b> No estimates were produced	<b>Oral HSV-1 prevalence:</b> <ul style="list-style-type: none"> <li>• 3,583.5 million oral HSV-1 prevalent infections among individuals aged 0-49 years</li> <li>• Oral HSV-1 prevalence of 63.6%</li> </ul>	<b>Oral HSV-1 prevalence:</b> <ul style="list-style-type: none"> <li>• 3,448.9 million oral HSV-1 prevalent infections among individuals aged 0-49 years</li> <li>• Oral HSV-1 prevalence of 58.6%</li> </ul>
<b>Genital HSV-1 prevalence:</b> <ul style="list-style-type: none"> <li>• 140.0 million genital HSV-1 prevalent infections among individuals aged 15-49 years</li> <li>• Genital HSV-1 prevalence of 4.0%</li> </ul>	<b>Genital HSV-1 prevalence:</b> <ul style="list-style-type: none"> <li>• 192.0 million genital HSV-1 prevalent infections among individuals aged 15-49 years</li> <li>• Genital HSV-1 prevalence of 5.2%</li> </ul>	<b>Genital HSV-1 prevalence:</b> <ul style="list-style-type: none"> <li>• 376.2 million genital HSV-1 prevalent infections among individuals aged 15-49 years</li> <li>• Genital HSV-1 prevalence of 10.2%</li> </ul>
<b>HSV-2 Incidence:</b> <ul style="list-style-type: none"> <li>• 19.2 million new HSV-2 infections among individuals aged 15-49 years</li> <li>• HSV-2 incidence rate of 0.5%</li> </ul>	<b>HSV-2 Incidence:</b> <ul style="list-style-type: none"> <li>• 23.9 million new HSV-2 infections among individuals aged 15-49 years</li> <li>• HSV-2 incidence rate of 0.6%</li> </ul>	<b>HSV-2 Incidence:</b> <ul style="list-style-type: none"> <li>• 25.6 million new HSV-2 infections among individuals aged 15-49 years</li> <li>• HSV-2 incidence rate of 0.7%</li> </ul>
<b>HSV-2 prevalence:</b> <ul style="list-style-type: none"> <li>• 417.3 million HSV-2 prevalent infections among individuals aged 15-49 years</li> <li>• HSV-2 prevalence of 11.3%</li> </ul>	<b>HSV-2 prevalence:</b> <ul style="list-style-type: none"> <li>• 491.5 million HSV-2 prevalent infections among individuals aged 15-49 years</li> <li>• HSV-2 prevalence of 13.2%</li> </ul>	<b>HSV-2 prevalence:</b> <ul style="list-style-type: none"> <li>• 519.5 million HSV-2 prevalent infections among individuals aged 15-49 years</li> <li>• HSV-2 prevalence of 13.3%</li> </ul>
<b>GUD caused by HSV-1:</b> No estimates were produced	<b>GUD caused by HSV-1:</b> <ul style="list-style-type: none"> <li>• 9.2 million individuals living with GUD due to HSV-1 infection among individuals aged 15-49 years</li> <li>• Prevalence of GUD caused by HSV-1 of 0.2%</li> </ul>	<b>GUD caused by HSV-1:</b> <ul style="list-style-type: none"> <li>• 16.7 million individuals living with GUD due to HSV-1 infection among individuals aged 15-49 years</li> <li>• Prevalence of GUD caused by HSV-1 of 0.5%</li> </ul>
<b>GUD caused by HSV-2:</b> No estimates were produced	<b>GUD caused by HSV-2:</b> <ul style="list-style-type: none"> <li>• 177.7 million individuals living with GUD due to HSV-2 infection among individuals aged 15-49 years</li> <li>• Prevalence of GUD caused by HSV-2 of 4.8%</li> </ul>	<b>GUD caused by HSV-2:</b> <ul style="list-style-type: none"> <li>• 187.9 million individuals living with GUD due to HSV-2 infection among individuals aged 15-49 years</li> <li>• Prevalence of GUD caused by HSV-2 of 4.8%</li> </ul>

Abbreviations: GUD = Genital ulcer disease, HSV = Herpes simplex virus, WHO = World Health Organization.




**Figure S1.** Model fits for HSV-2 prevalence for each WHO region.



Abbreviations: HSV = Herpes simplex virus, WHO = World Health Organization.  
Regions are per World Health Organization definitions.

**Figure S2.** Model fits for HSV-1 prevalence (any site; oral and genital) for each WHO region.



Abbreviations: HSV = Herpes simplex virus, WHO = World Health Organization.  
Regions are per World Health Organization definitions.

**Table S6.** Global and regional estimates of the number of people aged 50-99 years with prevalent HSV-1 or HSV-2 infection in 2020, by sex.

WHO Region	Number of people with prevalent infection in millions by sex					
	HSV-1 (any site, oral or genital)			HSV-2		
	Female	Male	Both	Female	Male	Both
<b>AFR</b>	58.2	51.3	<b>109.4</b>	45.7	28.0	<b>73.7</b>
<b>AMR</b>	119.6	97.7	<b>217.3</b>	58.0	28.9	<b>86.9</b>
<b>EMR</b>	40.4	41.2	<b>81.5</b>	3.1	3.6	<b>6.7</b>
<b>EUR</b>	158.8	104.9	<b>263.6</b>	36.0	16.5	<b>52.5</b>
<b>SEAR</b>	150.1	145.7	<b>295.7</b>	37.7	20.3	<b>58.1</b>
<b>WPR</b>	286.0	270.0	<b>555.9</b>	73.4	37.8	<b>111.2</b>
<b>Global</b>	<b>813.0</b>	<b>710.6</b>	<b>1,523.6</b>	<b>254.0</b>	<b>135.2</b>	<b>389.1</b>

Abbreviations: AFR = African Region, AMR = Region of the Americas, EMR = Eastern Mediterranean Region, EUR = European Region, HSV = Herpes simplex virus, SEAR = South-East Asia region, WHO = World Health Organization, WPR = Western Pacific Region.

Numbers are the year 2020 estimated number of people living with HSV-1 and HSV-2 infections. Numbers do not always sum exactly to the totals due to rounding. Regions are per World Health Organization definitions.

**Table S7.** Global and regional estimates of GUD person-days due to HSV-2 or HSV-1 among the population aged 15-49 years in 2020, by age and sex.

Sex	WHO region	Number of GUD person-days in millions by age group								
		15-19 years	20-24 years	25-29 years	30-34 years	35-39 years	40-44 years	45-49 years	All ages	95% UI <sup>a</sup>
		<b>HSV-2</b>								
Females	AFR	187	269	321	341	335	303	264	2,019	1,270-3,365
	AMR	45	82	121	151	175	190	200	964	574-1,674
	EMR	5	8	12	16	17	17	16	91	26-415
	EUR	14	25	42	63	77	89	101	411	221-767
	SEAR	44	77	110	138	162	173	179	883	535-1,505
	WPR	36	68	112	181	184	208	283	1,072	538-2,315
	Overall	330	530	717	890	951	978	1,044	5,440	3,581-9,436
Males	AFR	106	157	193	211	212	197	176	1,253	767-2,157
	AMR	24	44	66	82	95	102	108	520	307-932
	EMR	6	10	15	20	22	22	21	116	46-291
	EUR	8	15	24	36	44	50	56	232	110-498
	SEAR	26	46	64	80	93	98	102	509	274-985
	WPR	21	39	64	102	103	117	160	606	196-1,813
	Overall	190	311	427	530	568	586	622	3,235	2,038-5,508
Both	Global	520	841	1,144	1,421	1,519	1,564	1,666	8,675	5,632-15,068
		<b>HSV-1</b>								
Females	AFR	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0-7
	AMR	5	4	4	3	2	2	1	21	13-66
	EMR	2	1	0.5	0.2	0.1	0.0	0.0	4	0-16
	EUR	4	3	2	2	2	1	0.9	15	9-50
	SEAR	9	5	3	2	1	0.6	0.3	20.6	2-72
	WPR	7	5	4	3	2	1	0.8	22	12-82
	Overall	27	18	13	10	7	5	3	83	50-275
Males	AFR	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0-7
	AMR	5	4	3	3	2	1	1	19	12-62
	EMR	2	1	0.5	0.3	0.0	0.0	0.0	4	0-18
	EUR	3	2	2	2	1	1	1	11	6-37
	SEAR	9	6	3	2	1	0.6	0.3	22.4	2-78
	WPR	8	6	4	3	2	1	0.8	24	13-87
	Overall	28	19	13	10	6	4	3	83	48-264
Both	Global	55	37	26	19	13	9	6	166	98-562
		<b>HSV-2 and HSV-1</b>								
Global	Females	357	548	730	900	958	983	1,047	5,523	3,676-9,539
	Males	218	330	440	540	574	590	625	3,318	2,120-5,805
	Both	575	878	1,170	1,440	1,532	1,573	1,672	8,841	5,795-15,425

Abbreviations: AFR = African Region, AMR = Region of the Americas, EMR = Eastern Mediterranean Region, EUR = European Region, GUD = Genital ulcer disease, HSV = Herpes simplex virus, SEAR = South-East Asia region, UI = Uncertainty interval, WHO = World Health Organization, WPR = Western Pacific Region.

Abbreviations: AFR = Africa, AMR = Americas, EMR = Eastern Mediterranean, EUR = Europe, GUD = Genital ulcer disease, HSV = Herpes simplex virus, SEAR = South-East Asia, UI = Uncertainty interval, WHO = World Health Organization, WPR = Western Pacific.

<sup>a</sup> 95% UI of the total number of GUD person-days in millions.

Numbers (N) are the year 2020 estimated person-days of GUD caused by HSV-1 and/or HSV-2 infection. Numbers do not always sum exactly to the totals due to rounding.

Regions are per World Health Organization definitions.

**Table S8.** Global and regional estimates of the number and percentage of the population aged 0-49 years with incident HSV-1 infection (any site, oral or genital) in 2020, by age and sex.

Sex	WHO region	Number of people with incident HSV-1 infection in millions (population incidence, %) by age group												
		0-4 years	5-9 years	10-14 years	15-19 years	20-24 years	25-29 years	30-34 years	35-39 years	40-44 years	45-49 years	All ages		
		N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (95% UI <sup>a</sup> )	% (95% UI <sup>b</sup> )	
Females	AFR	16.5 (19.3)	2.3 (3.0)	0.3 (0.5)	<0.1 <sup>c</sup> (0.1)	<0.1 <sup>d</sup> (0.0)	<0.1 <sup>d</sup> (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	19.1 (16.4-23.5)	3.8 (3.3-4.7)
	AMR	1.2 (3.4)	1.0 (2.8)	0.8 (2.3)	0.7 (1.9)	0.6 (1.5)	0.5 (1.3)	0.4 (1.0)	0.3 (0.9)	0.2 (0.7)	0.2 (0.6)	0.2 (0.6)	6.0 (5.5-6.4)	1.7 (1.5-1.8)
	EMR	3.5 (8.4)	1.6 (4.1)	0.7 (2.0)	0.3 (1.0)	0.1 (0.5)	0.1 (0.2)	<0.1 <sup>c</sup> (0.1)	<0.1 <sup>c</sup> (0.1)	<0.1 <sup>d</sup> (0.0)	<0.1 <sup>d</sup> (0.0)	<0.1 <sup>d</sup> (0.0)	6.4 (5.2-7.4)	2.1 (1.8-2.5)
	EUR	1.2 (4.5)	1.0 (3.4)	0.7 (2.6)	0.5 (2.0)	0.4 (1.5)	0.3 (1.2)	0.3 (0.9)	0.2 (0.7)	0.2 (0.5)	0.1 (0.4)	0.1 (0.4)	4.9 (4.5-5.2)	1.7 (1.5-1.8)
	SEAR	4.8 (5.9)	3.0 (3.6)	1.9 (2.2)	1.2 (1.4)	0.7 (0.9)	0.4 (0.5)	0.3 (0.3)	0.1 (0.2)	0.1 (0.1)	<0.1 <sup>c</sup> (0.1)	<0.1 <sup>c</sup> (0.1)	12.6 (10.0-13.7)	1.6 (1.3-1.8)
	WPR	3.7 (6.6)	2.5 (4.3)	1.6 (2.8)	1.0 (1.9)	0.7 (1.2)	0.5 (0.8)	0.4 (0.5)	0.2 (0.3)	0.1 (0.2)	0.1 (0.1)	0.1 (0.1)	10.9 (10.5-11.0)	1.7 (1.7-1.7)
	Overall	30.9 (9.4)	11.4 (3.5)	6.1 (1.8)	3.8 (1.3)	2.6 (0.9)	1.9 (0.6)	1.4 (0.5)	0.9 (0.3)	0.6 (0.3)	0.5 (0.2)	0.5 (0.2)	60.0 (56.1-64.6)	2.1 (2.0-2.3)
Males	AFR	16.9 (19.3)	2.3 (3.0)	0.3 (0.5)	<0.1 <sup>c</sup> (0.1)	<0.1 <sup>d</sup> (0.0)	<0.1 <sup>d</sup> (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	19.7 (17.0-24.0)	3.9 (3.3-4.7)
	AMR	1.2 (3.2)	1.0 (2.6)	0.8 (2.2)	0.7 (1.8)	0.6 (1.4)	0.5 (1.2)	0.4 (1.0)	0.3 (0.8)	0.2 (0.6)	0.2 (0.5)	0.2 (0.5)	5.8 (5.2-6.3)	1.6 (1.4-1.7)
	EMR	3.7 (8.4)	1.7 (4.1)	0.7 (2.0)	0.3 (1.0)	0.2 (0.5)	0.1 (0.2)	<0.1 <sup>c</sup> (0.1)	<0.1 <sup>c</sup> (0.1)	<0.1 <sup>d</sup> (0.0)	<0.1 <sup>d</sup> (0.0)	<0.1 <sup>d</sup> (0.0)	6.8 (5.5-7.8)	2.1 (1.7-2.4)
	EUR	1.1 (4.0)	0.9 (2.9)	0.6 (2.2)	0.4 (1.6)	0.3 (1.2)	0.3 (0.9)	0.2 (0.7)	0.2 (0.5)	0.1 (0.4)	0.1 (0.3)	0.1 (0.3)	4.2 (3.8-4.4)	1.4 (1.2-1.5)
	SEAR	5.2 (5.9)	3.3 (3.6)	2.1 (2.2)	1.3 (1.4)	0.8 (0.9)	0.5 (0.5)	0.3 (0.3)	0.2 (0.2)	0.1 (0.1)	<0.1 <sup>c</sup> (0.1)	<0.1 <sup>c</sup> (0.1)	13.7 (10.7-14.9)	1.6 (1.3-1.8)
	WPR	4.1 (6.6)	2.8 (4.3)	1.8 (2.8)	1.1 (1.9)	0.8 (1.2)	0.6 (0.8)	0.4 (0.5)	0.2 (0.3)	0.2 (0.2)	0.1 (0.1)	0.1 (0.1)	12.1 (11.7-12.3)	1.8 (1.7-1.8)
	Overall	32.4 (9.3)	11.9 (3.5)	6.4 (1.9)	3.9 (1.2)	2.6 (0.9)	1.8 (0.6)	1.3 (0.4)	0.9 (0.3)	0.6 (0.2)	0.4 (0.2)	0.4 (0.2)	62.2 (57.9-66.6)	2.1 (1.9-2.2)
<b>Both</b>	<b>Global</b>	63.2 (9.4)	23.3 (3.5)	12.5 (2.0)	7.7 (1.3)	5.2 (0.9)	3.7 (0.6)	2.7 (0.5)	1.8 (0.3)	1.2 (0.2)	0.9 (0.2)	122.2 (116.2-128.6)	2.1 (2.0-2.2)	

Abbreviations: AFR = African Region, AMR = Region of the Americas, EMR = Eastern Mediterranean Region, EUR = European Region, HSV = Herpes simplex virus, SEAR = South-East Asia region, UI = Uncertainty interval, WHO = World Health Organization, WPR = Western Pacific Region.

<sup>a</sup> 95% UI of the total number of infected people in millions.

<sup>b</sup> 95% UI of percentage incidence.

<sup>c</sup> Numbers are <50,000 but ≥10,000.

<sup>d</sup> Number are <10,000 but ≥1,000.

Numbers (N) are the estimated number of people newly infected with HSV-1 during 2020. Numbers do not always sum exactly to the totals due to rounding.

Incidences (%) are the percentage of infected people in the age-, sex-, and region-specific population.

Regions are per World Health Organization definitions.

**Table S9.** Global and regional estimates of the number and percentage of the population aged 0-49 years with prevalent HSV-1 infection (any site, oral or genital) in 2020, by age and sex.

Sex	WHO region	Number of people with prevalent HSV-1 infection in millions (population prevalence, %) by age group											All ages	
		0-4 years	5-9 years	10-14 years	15-19 years	20-24 years	25-29 years	30-34 years	35-39 years	40-44 years	45-49 years	N (95% UI <sup>a</sup> )	% (95% UI <sup>b</sup> )	
		N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)			
Females	AFR	37.2 (57.9)	67.1 (89.5)	63.9 (94.4)	55.8 (95.1)	48.1 (95.3)	41.5 (95.3)	35.9 (95.3)	30.6 (95.3)	24.9 (95.3)	20.1 (95.3)	425.2 (381.9-446.7)	85.1 (76.4-89.4)	
	AMR	2.5 (8.8)	8.2 (24.1)	13.0 (36.6)	17.2 (46.8)	21.1 (55.2)	24.2 (62.1)	25.6 (67.7)	26.3 (72.3)	25.7 (76.1)	25.0 (79.2)	188.9 (165.2-210.9)	51.7 (45.3-57.8)	
	EMR	7.5 (23.1)	18.8 (50.5)	22.0 (63.9)	22.3 (70.4)	22.2 (73.6)	22.1 (75.2)	21.4 (75.9)	19.0 (76.3)	15.9 (76.5)	13.0 (76.6)	184.0 (137.9-207.1)	61.7 (46.2-69.4)	
	EUR	2.5 (11.8)	8.2 (31.0)	12.0 (45.7)	14.1 (56.8)	16.7 (65.3)	20.9 (71.7)	25.4 (76.6)	26.5 (80.3)	26.9 (83.1)	27.1 (85.2)	180.3 (153.4-203.9)	61.4 (52.2-69.4)	
	SEAR	10.0 (15.7)	29.5 (37.8)	43.2 (51.5)	51.1 (59.9)	54.6 (65.1)	55.0 (68.3)	54.5 (70.3)	52.7 (71.6)	47.9 (72.3)	43.5 (72.8)	442.0 (288.6-520.7)	56.7 (37.0-66.8)	
	WPR	7.7 (17.4)	23.3 (42.8)	32.2 (59.6)	37.8 (70.5)	44.5 (77.7)	52.8 (82.5)	67.9 (85.6)	57.7 (87.6)	55.9 (88.9)	67.3 (89.8)	447.0 (404.2-479.9)	71.0 (64.2-76.2)	
	Overall	67.4 (20.6)	155.0 (48.4)	186.3 (60.4)	198.3 (67.4)	207.2 (72.0)	216.5 (75.4)	230.7 (78.3)	212.8 (79.8)	197.2 (81.3)	196.0 (82.9)	1,867.4 (1,695.3-1,969.7)	65.2 (59.2-68.7)	
	Both	Global	137.7 (20.4)	317.2 (47.9)	382.1 (59.8)	406.7 (66.7)	423.6 (71.2)	440.7 (74.5)	465.3 (77.2)	425.6 (78.6)	392.0 (79.9)	388.2 (81.5)	3,779.1 (3,510.3-3,921.6)	64.2 (59.7-66.7)
Males	AFR	38.3 (57.9)	68.8 (89.5)	65.3 (94.4)	56.8 (95.1)	48.6 (95.3)	41.6 (95.3)	35.7 (95.3)	30.1 (95.3)	24.4 (95.3)	19.5 (95.3)	429.1 (388.5-450.8)	84.9 (76.9-89.2)	
	AMR	2.5 (8.4)	8.0 (22.7)	12.7 (34.4)	16.7 (44.0)	20.2 (51.7)	23.1 (58.1)	24.0 (63.2)	24.1 (67.5)	23.1 (70.9)	22.2 (73.7)	176.7 (150.9-204.5)	47.8 (40.8-55.4)	
	EMR	7.9 (23.1)	19.9 (50.5)	23.2 (63.9)	23.6 (70.4)	23.6 (73.6)	24.1 (75.2)	23.6 (75.9)	20.9 (76.3)	17.6 (76.5)	14.3 (76.6)	198.8 (145.8-222.6)	61.9 (45.4-69.4)	
	EUR	2.3 (10.3)	7.5 (26.8)	10.8 (39.1)	12.6 (48.1)	14.8 (54.8)	18.2 (59.8)	21.5 (63.5)	22.0 (66.2)	21.8 (68.2)	21.7 (69.7)	153.2 (123.7-175.4)	50.7 (40.9-58.0)	
	SEAR	10.9 (15.7)	31.9 (37.8)	47.0 (51.5)	56.1 (59.9)	59.8 (65.1)	59.5 (68.3)	57.7 (70.3)	55.3 (71.6)	49.6 (72.3)	44.6 (72.8)	472.5 (303.0-560.2)	56.5 (36.3-67.0)	
	WPR	8.5 (17.4)	26.1 (42.8)	36.6 (59.6)	42.6 (70.5)	49.5 (77.7)	57.6 (82.5)	72.0 (85.6)	60.4 (87.6)	58.3 (88.9)	69.8 (89.8)	481.4 (437.8-517.0)	70.5 (64.1-75.7)	
	Overall	70.3 (20.2)	162.3 (47.5)	195.7 (59.3)	208.4 (66.1)	216.4 (70.5)	224.2 (73.6)	234.6 (76.2)	212.8 (77.4)	194.8 (78.6)	192.2 (80.1)	1,911.7 (1,722.8-2,023.9)	63.4 (57.1-67.1)	

Abbreviations: AFR = African Region, AMR = Region of the Americas, EMR = Eastern Mediterranean Region, EUR = European Region, HSV = Herpes simplex virus, SEAR = South-East Asia region, UI = Uncertainty interval, WHO = World Health Organization, WPR = Western Pacific Region.

<sup>a</sup> 95% UI of the total number of infected people in millions.

<sup>b</sup> 95% UI of percentage prevalence.

Numbers (N) are the year 2020 estimated number of people living with HSV-1 infection. Numbers do not always sum exactly to the totals due to rounding.

Prevalences (%) are the percentage of infected people in the age-, sex-, and region-specific population.

Regions are per World Health Organization definitions.

**Table S10.** Global and regional estimates of the number and percentage of the population aged 0-49 years with prevalent oral HSV-1 infection in 2020, by age and sex.

Sex	WHO region	Number of people with prevalent oral HSV-1 infection in millions (population prevalence, %) by age group											All ages	
		0-4 years	5-9 years	10-14 years	15-19 years	20-24 years	25-29 years	30-34 years	35-39 years	40-44 years	45-49 years	N (95% UI <sup>a</sup> )	% (95% UI <sup>b</sup> )	
		N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)			
Females	AFR	37.2 (57.9)	67.1 (89.5)	63.9 (94.4)	55.8 (95.0)	48.0 (95.0)	41.4 (95.1)	35.9 (95.1)	30.5 (95.1)	24.9 (95.1)	20.1 (95.1)	424.7 (372.9-446.7)	85.0 (74.6-89.4)	
	AMR	2.5 (8.8)	8.2 (24.1)	13.0 (36.6)	16.3 (43.7)	18.0 (46.8)	19.4 (49.3)	19.5 (51.3)	19.3 (53.0)	18.4 (54.4)	17.6 (55.5)	152.2 (129.8-174.7)	41.7 (35.6-47.9)	
	EMR	7.5 (23.1)	18.8 (50.5)	22.0 (63.9)	21.8 (68.7)	21.1 (69.9)	20.7 (70.5)	19.9 (70.7)	17.7 (70.9)	14.7 (70.9)	12.1 (71.0)	176.3 (118.5-206.7)	59.1 (39.7-69.3)	
	EUR	2.5 (11.8)	8.2 (31.0)	12.0 (45.7)	13.4 (53.5)	14.6 (56.6)	17.3 (58.9)	20.2 (60.7)	20.6 (62.1)	20.4 (63.1)	20.3 (63.9)	149.5 (121.4-178.2)	50.9 (41.3-60.6)	
	SEAR	10.0 (15.7)	29.5 (37.8)	43.2 (51.5)	49.5 (57.6)	50.0 (59.5)	49.0 (60.6)	47.6 (61.4)	45.6 (61.8)	41.2 (62.1)	37.2 (62.2)	402.8 (231.3-516.6)	51.7 (29.7-66.3)	
	WPR	7.7 (17.4)	23.3 (42.8)	32.2 (59.6)	36.5 (67.4)	40.3 (70.0)	46.1 (71.8)	57.9 (72.9)	48.5 (73.6)	46.7 (74.1)	55.8 (74.4)	395.0 (340.5-443.3)	62.7 (54.1-70.4)	
	Overall	67.4 (20.6)	155.0 (48.4)	186.3 (60.4)	193.3 (65.7)	192.1 (66.8)	193.8 (67.5)	201.0 (68.2)	182.2 (68.3)	166.2 (68.5)	163.1 (18.9)	1,700.4 (1,501.7-1,841.0)	59.3 (52.4-64.2)	
Males	AFR	38.3 (57.9)	68.8 (89.5)	65.3 (94.4)	56.7 (95.0)	48.5 (95.0)	41.5 (95.1)	35.6 (95.1)	30.0 (95.1)	24.4 (95.1)	19.5 (95.1)	428.6 (380.5-450.8)	84.8 (75.3-89.2)	
	AMR	2.5 (8.4)	8.0 (22.7)	12.7 (34.4)	15.8 (41.1)	17.3 (43.9)	18.5 (46.2)	18.3 (48.1)	17.8 (49.6)	16.6 (50.9)	15.7 (51.9)	143.3 (118.8-172.3)	38.8 (32.2-46.6)	
	EMR	7.9 (23.1)	19.9 (50.5)	23.2 (63.9)	23.1 (68.7)	22.5 (69.9)	22.7 (70.5)	22.0 (70.7)	19.4 (70.9)	16.3 (70.9)	13.3 (71.0)	190.3 (124.3-222.1)	59.3 (38.7-69.2)	
	EUR	2.3 (10.3)	7.5 (26.8)	10.8 (39.1)	12.0 (45.4)	13.0 (47.9)	15.2 (49.7)	17.4 (51.0)	17.4 (52.0)	16.9 (52.8)	16.6 (53.3)	129.0 (97.9-157.3)	42.7 (32.4-52.1)	
	SEAR	10.9 (15.7)	31.9 (37.8)	47.0 (51.5)	54.4 (57.6)	54.8 (59.5)	53.0 (60.6)	50.5 (61.4)	47.8 (61.8)	42.6 (62.1)	38.2 (62.2)	431.0 (242.9-556.4)	51.6 (29.1-66.6)	
	WPR	8.5 (17.4)	26.1 (42.8)	36.6 (59.6)	41.1 (67.4)	44.8 (70.0)	50.3 (71.8)	61.4 (72.9)	50.8 (73.6)	48.7 (74.1)	57.9 (74.4)	426.2 (371.0-477.7)	62.4 (54.3-70.0)	
	Overall	70.3 (20.2)	162.3 (47.5)	195.7 (59.3)	203.2 (64.4)	200.9 (65.5)	201.1 (66.1)	205.2 (66.7)	183.2 (66.7)	165.4 (66.8)	161.1 (67.2)	1,748.5 (1,531.6-1,905.2)	58.0 (50.8-63.2)	
Both	Global	137.7 (20.4)	317.2 (47.9)	382.1 (59.8)	396.5 (65.0)	393.0 (66.1)	394.9 (66.8)	406.3 (67.4)	365.4 (67.5)	331.7 (67.6)	324.2 (68.1)	3,448.9 (3,144.9-3,655.2)	58.6 (53.5-62.1)	

Abbreviations: AFR = African Region, AMR = Region of the Americas, EMR = Eastern Mediterranean Region, EUR = European Region, HSV = Herpes simplex virus, SEAR = South-East Asia region, UI = Uncertainty interval, WHO = World Health Organization, WPR = Western Pacific Region.

<sup>a</sup> 95% UI of the total number of infected people in millions.

<sup>b</sup> 95% UI of percentage prevalence.

Numbers (N) are the year 2020 estimated number of people living with oral HSV-1 infection. Numbers do not always sum exactly to the totals due to rounding.

Prevalences (%) are the percentage of infected people in the age-, sex-, and region-specific population.

Regions are per World Health Organization definitions.

## References

1. AlMukdad S, Harfouche M, Wettstein A, Abu-Raddad LJ: **Epidemiology of herpes simplex virus type 2 in Asia: A systematic review, meta-analysis, and meta-regression.** *Lancet Reg Health West Pac* 2021, **12**:100176.
2. Khadr L, Harfouche M, Omori R, Schwarzer G, Chemaitelly H, Abu-Raddad LJ: **The Epidemiology of Herpes Simplex Virus Type 1 in Asia: Systematic Review, Meta-analyses, and Meta-regressions.** *Clin Infect Dis* 2019, **68**(5):757-772.
3. Alareeki A, Osman AMM, Khandakji MN, Looker KJ, Harfouche M, Abu-Raddad LJ: **Epidemiology of herpes simplex virus type 2 in Europe: systematic review, meta-analyses, and meta-regressions.** *Lancet Reg Health Eur* 2023, **25**:100558.
4. Yousuf W, Ibrahim H, Harfouche M, Abu Hijleh F, Abu-Raddad L: **Herpes simplex virus type 1 in Europe: systematic review, meta-analyses and meta-regressions.** *BMJ Glob Health* 2020, **5**(7):e002388.
5. Harfouche M, Maalmi H, Abu-Raddad LJ: **Epidemiology of herpes simplex virus type 2 in Latin America and the Caribbean: systematic review, meta-analyses and metaregressions.** *Sex Transm Infect* 2021, **97**(7):490-500.
6. Sukik L, Alyafei M, Harfouche M, Abu-Raddad LJ: **Herpes simplex virus type 1 epidemiology in Latin America and the Caribbean: Systematic review and meta-analyses.** *PloS one* 2019, **14**(4):e0215487.
7. Chaabane S, Harfouche M, Chemaitelly H, Schwarzer G, Abu-Raddad LJ: **Herpes simplex virus type 1 epidemiology in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions.** *Sci Rep* 2019, **9**(1):1136.
8. Harfouche M, Alareeki A, Osman AMM, Alaama AS, Hermez JG, Abu-Raddad LJ: **Epidemiology of herpes simplex virus type 2 in the Middle East and North Africa: Systematic review, meta-analyses, and meta-regressions.** *J Med Virol* 2023, **95**(3):e28603.
9. Harfouche M, Abu-Hijleh FM, James C, Looker KJ, Abu-Raddad LJ: **Epidemiology of herpes simplex virus type 2 in sub-Saharan Africa: Systematic review, meta-analyses, and meta-regressions.** *EClinicalMedicine* 2021, **35**:100876.
10. Harfouche M, Chemaitelly H, Abu-Raddad LJ: **Herpes simplex virus type 1 epidemiology in Africa: Systematic review, meta-analyses, and meta-regressions.** *J Infect* 2019, **79**(4):289-299.
11. AlMukdad S, Farooqui US, Harfouche M, Aldos L, Abu-Raddad LJ: **Epidemiology of Herpes Simplex Virus Type 2 in Canada, Australia, and New Zealand: Systematic Review, Meta-Analyses, and Meta-Regressions.** *Sex Transm Dis* 2022, **49**(6):403-413.
12. AlMukdad S, Harfouche M, Farooqui US, Aldos L, Abu-Raddad LJ: **Epidemiology of Herpes Simplex Virus Type 1 in Canada: Systematic Review, Meta-Analyses, and Meta-Regressions (under review).** 2022.
13. AlMukdad S, Harfouche M, Farooqui US, Aldos L, Abu-Raddad LJ: **Epidemiology of herpes simplex virus type 1 and genital herpes in Australia and New Zealand: systematic review, meta-analyses and meta-regressions.** *Epidemiol Infect* 2023, **151**:e33.
14. **World Population Prospects 2022: Summary of Results.** UN DESA/POP/2022/TR/NO. 3. [\[https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/wpp2022\\_summary\\_of\\_results.pdf\]](https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/wpp2022_summary_of_results.pdf)
15. James CR, Harfouche M, Welton NJ, Turner KME, AbuRaddad LJ, Gottlieb SL, Looker KJ: **Global and regional estimates of herpes simplex virus infection prevalence and incidence in 2016.** *Bulletin of the World Health Organization* 2020, **98**:315-329.
16. Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, Grove JT, Hogan DR, Hogan MC, Horton R *et al*: **Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement.** *The Lancet* 2016, **388**(10062):e19-e23.



17. Looker KJ, Magaret AS, May MT, Turner KM, Vickerman P, Gottlieb SL, Newman LM: **Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012.** *PloS one* 2015, **10**(10):e0140765.
18. Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM: **Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012.** *PloS one* 2015, **10**(1):e114989.
19. Looker KJ, Johnston C, Welton NJ, James C, Vickerman P, Turner KME, Boily MC, Gottlieb SL: **The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study.** *BMJ Glob Health* 2020, **5**(3):e001875.